var docs;if (!docs) docs =[]; docs["84"]={"8400":"<p><b>Title</b> Diethylpropion / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Diethylpropion. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caution patients receiving diethylpropion that its use may adversely affect the ability to drive or safely engage in potentially hazardous activities following alcohol consumption.</p> \n<p><b>Discussion</b> Diethylpropion US prescribing information warns that patients receiving the agent should be cautioned that there is a potential for adverse reactions when consuming alcohol, as the combination may affect the patient's ability to drive or engage safely in potentially hazardous activities.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tenuate</i> (diethylpropion) [prescribing information]. Bridgewater, NJ: Merrell Pharmaceuticals Inc; September 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8401":"<p><b>Title</b> Doxycycline / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alcohol (Ethyl) may decrease the serum concentration of Doxycycline. Specifically, doxycycline exposure may be lower in alcoholic patients. The specific role of Alcohol (Ethyl) in causing this is unclear. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study, the estimated half-life and urinary excretion of doxycycline were lower (by roughly 29% and 22%, respectively) in 6 alcoholic patients without detectable renal or hepatic dysfunction than in 6 healthy volunteers.<sup>1</sup> In another small study, acute ingestion of whiskey (containing around 1 g/kg alcohol) had no measurable impact on doxycycline AUC in healthy volunteers, while a red wine containing a similar amount of alcohol delayed doxycycline absorption and decreased its 24 hour AUC by around 28%.<sup>2</sup> Other wines (2 red, 2 white) tested in a parallel study in the same report were associated with similar doxycycline exposure patterns when compared to the original red wine.<br><br>The potential mechanism of interaction between alcohol and doxycycline is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neuvonen PJ, Penttila O, Roos M, Tirkkonen J. Effect of long-term alcohol consumption on the half-life of tetracycline and doxycycline in man. <i>Int J Clin Pharmacol Biopharm</i>. 1976;14(4):303-307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1002368\">[PubMed 1002368]</a></p>\n<p>2. Mattila MJ, Laisi U, Linnoila M, Salonen R. Effect of alcoholic beverages on the pharmacokinetics of doxycycline in man. <i>Acta Pharmacol Toxicol (Copenh)</i>. 1982;50(5):370-373. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7113712\">[PubMed 7113712]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8402":"<p><b>Title</b> Erythromycin (Systemic) / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Alcohol (Ethyl). This effect has only been described with intravenous Erythromycin (Systemic) administered immediately before consumption of Alcohol (Ethyl). Alcohol (Ethyl) may decrease the serum concentration of Erythromycin (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, intravenous erythromycin (3 mg/kg, administered over 20 minutes) increased the maximum blood concentration (Cmax) and AUC of alcohol (0.5 g/kg, taken with a meal immediately following erythromycin) by around 40% and 14%, respectively.<sup>1</sup> In contrast, in a study of 10 healthy volunteers, oral erythromycin (500 mg base 3 times daily for 7 days) had no impact on ethanol (0.8 g/kg) Cmax or AUC.<sup>2</sup> Subjects' self-rated levels of intoxication were similarly unaffected. Finally, in a third study of 9 healthy volunteers, coadministration of a single oral dose of erythromycin ethylsuccinate (500 mg) with alcohol (undisclosed standard dose given concurrently with and 2.5 hours following erythromycin) decreased the AUC of erythromycin by roughly 27%.<sup>3</sup> Blood alcohol pharmacokinetics were not estimated.<br><br>The mechanisms of the above effects are unknown. Alcohol reductions in gastric emptying rate could theoretically account for a small delay in the time of first detection of erythromycin in plasma detected in the third report above.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Edelbroek MA, Horowitz M, Wishart JM, Akkermans LM. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects. <i>J Nucl Med</i>. 1993;34(4):582-588. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8455074\">[PubMed 8455074]</a></p>\n<p>2. Min DI, Noormohamed SE, Flanigan MJ. Effect of erythromycin on ethanol's pharmacokinetics and perception of intoxication. <i>Pharmacotherapy</i>. 1995;15(2):164-169. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7624263\">[PubMed 7624263]</a></p>\n<p>3. Morasso MI, Chavez J, Gai MN, Arancibia A. Influence of alcohol consumption on erythromycin ethylsuccinate kinetics. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(10):426-429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2258252\">[PubMed 2258252]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8403":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Ceritinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ceritinib may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to the CYP3A4 substrate closely when using this combination. Concurrent use of ceritinib with a CYP3A4 substrate that has a narrow therapeutic index (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible. If such a combination must be used, consider using a reduced dose of the narrow therapeutic index CYP3A4 substrate.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this potential interaction are not available, but the ceritinib prescribing information notes that clinically relevant concentrations of ceritinib are likely capable of inhibiting CYP3A4.<sup>1</sup> Consequently, the prescribing information warns of potential interactions with CYP3A4 substrates and cautions that concurrent use with narrow therapeutic index CYP3A4 substrates should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8404":"<p><b>Title</b> CYP2C9 Substrates (High risk with Inhibitors) / Ceritinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ceritinib may increase the serum concentration of CYP2C9 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient response to the CYP2C9 substrate closely when using this combination. Concurrent use of ceritinib with a CYP2C9 substrate that has a narrow therapeutic index (eg, warfarin, phenytoin) should be avoided when possible. If such a combination must be used, consider using a reduced dose of the narrow therapeutic index CYP2C9 substrate.</p>\n<div>\n <p><b>CYP2C9 Substrates (High risk with Inhibitors) Interacting Members</b> Acenocoumarol, Benzbromarone, Celecoxib, ChlorproPAMIDE, FLUoxetine, Fosphenytoin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Lesinurad, Losartan, Meloxicam, Mestranol, Nateglinide, Phenytoin, Piroxicam (Systemic), SulfADIAZINE, Sulfamethoxazole, Sulfinpyrazone, SulfiSOXAZOLE, Tamoxifen, TOLBUTamide, Torsemide, Trimethoprim, Voriconazole, Warfarin</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this potential interaction are not available, but the ceritinib prescribing information notes that clinically relevant concentrations of ceritinib are likely capable of inhibiting CYP2C9.<sup>1</sup> Consequently, the prescribing information warns of potential interactions with CYP2C9 substrates and cautions that concurrent use with narrow therapeutic index CYP2C9 substrates should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zykadia (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8405":"<p><b>Title</b> Procainamide / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Alcohol (Ethyl) may increase serum concentrations of the active metabolite(s) of Procainamide. Specifically, concentrations of n-acetyl-procainamide may be increased. Alcohol (Ethyl) may decrease the serum concentration of Procainamide. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 11 healthy volunteers, coadministration of alcohol (0.73 g/kg once, then 0.11 g/kg hourly for 6 hours) increased the total clearance rate of procainamide (10 mg/kg single oral dose, starting 1.5 hours before the first ethanol dose) by roughly 34%.<sup>1</sup> Estimated renal clearance of procainamide and its acetylated metabolite N-acetylprocainamide (NAPA) was unchanged. In a parallel study of 8 healthy volunteers, ethanol pretreatment (0.73 g/kg 2 h prior to procainamide, then half that dose 1.5 hours after procainamide, then 0.11 g/kg hourly as above) increased procainamide (10 mg/kg single oral dose) total clearance by 25%.<sup>1</sup> The AUC of procainamide decreased (less than 20%) and the AUC of NAPA increased (around 21%) in this second study. The total AUC (procainamide plus NAPA) was similar between groups.<br><br>Ethanol treatment appears to reduce procainamide acetylation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Olsen H, Morland J. Ethanol-induced increase in procainamide acetylation in man. <i>Br J Clin Pharmacol</i>. 1982;13(2):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7059417\">[PubMed 7059417]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8406":"<p><b>Title</b> Umeclidinium / Verapamil</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Verapamil may increase the serum concentration of Umeclidinium. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The AUC of umeclidinium was an average of 37% to 39% higher with concurrent verapamil in a study of healthy volunteers (n=16) who received either inhaled umeclidinium alone (500 mcg/day) or inhaled umeclidinium and vilanterol (500 mcg/25 mcg daily) together with verapamil (240 mg/day for 5 days).<sup>1</sup> The maximum serum concentration (Cmax) was not significantly changed. Of note, the umeclidinium dose used in this study was 8-times higher than the recommended dose (62.5 mcg/day),<sup>2,3</sup> and no significant adverse effects of the interaction were noted.<br><br>The specific mechanism for this interaction is uncertain, but verapamil inhibition of umeclidinium efflux by p-glycoprotein is a possible explanation, as umeclidinium is a p-glycoprotein substrate.<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mehta R, Kelleher D, Preece A, Hughes S, Crater G. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. <i>Int J Chron Obstruct Pulmon Dis</i>. 2013;8:159-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23569370\">[PubMed 23569370]</a></p>\n<p>2. Incruse Ellipta (umeclidinium) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2014.</p>\n<p>3. Anoro Ellipta (umeclidinium and vilanterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.</p>\n<p>4. Incruse Ellipta (umeclidinium) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8407":"<p><b>Title</b> Rufinamide / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Rufinamide. Specifically, sleepiness and dizziness may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients receiving rufinamide that its use in combination with alcohol or other CNS depressants may cause additive CNS effects (particularly sleepiness and dizziness). This may adversely affect the ability to drive or safely engage in potentially hazardous activities following alcohol consumption.</p> \n<p><b>Discussion</b> Rufinamide US prescribing information warns that patients receiving the agent should be cautioned that there is a potential for additive CNS effects with alcohol or any other agent that may cause sleepiness or dizziness.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Banzel</i> (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8408":"<p><b>Title</b> CNS Depressants / Rufinamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Rufinamide may enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Caution patients receiving rufinamide that its use in combination with alcohol or other CNS depressants may cause additive CNS effects (particularly sleepiness and dizziness). This may adversely affect the ability to drive or safely engage in potentially hazardous activities.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Rufinamide US prescribing information warns that patients receiving the agent should be cautioned that there is a potential for additive CNS effects with alcohol or any other agent that may cause sleepiness or dizziness.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Banzel</i> (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; March 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8409":"<p><b>Title</b> TraZODone / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of TraZODone. Specifically, effects on sleepiness, dizziness, and manual dexterity may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Caution patients receiving trazodone that its use in combination with alcohol may cause additive CNS effects. This may adversely affect the ability to drive or safely engage in potentially hazardous activities following alcohol consumption.</p> \n<p><b>Discussion</b> Trazodone US prescribing information warns that patients receiving the agent should be cautioned that there is a potential for additive CNS effects with alcohol or any other agent that may cause sleepiness or dizziness.<sup>1</sup> Several deaths have been reported in patients who consumed trazodone in combination with alcohol and/or other CNS depressant drugs.<sup>1,2</sup> In a clinical study of healthy volunteers, alcohol consumption decreased manual dexterity in subjects given trazodone without having a clear impact on other measures of psychomotor function, memory, and subjective effects (drowsiness, inhibition, etc).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Oleptro</i> (trazodone) [prescribing information]. Princeton, NJ: Angelini Labopharm LLC; November 2012.</p>\n<p>2. Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. <i>J Clin Psychiatry</i>. 1986;47(11):544-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3771499\">[PubMed 3771499]</a></p>\n<p>3. Warrington SJ, Ankier SI, Turner P. An evaluation of possible interactions between ethanol and trazodone or amitriptyline. <i>Br J Clin Pharmacol</i>. 1984;18(4):549-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487494\">[PubMed 6487494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8410":"<p><b>Title</b> Amitriptyline / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Topiramate may enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to this combination closely. In particular, monitor patients for excessive CNS depression and/or exaggerated amitriptyline effects (including anticholinergic effects, etc.). This interaction may be more significant in some individual patients, and decisions on any need for therapy adjustment should be based more on clinical response than solely on serum amitriptyline and/or nortriptyline concentrations.</p> \n<p><b>Discussion</b> According to the topiramate prescribing information, the amitriptyline AUC and maximum serum concentration (Cmax) were 12% higher with concurrent topiramate in a study of 18 healthy volunteers who received both amitriptyline 25 mg/day and topiramate (200 mg/day).<sup>1</sup> It was also noted that the increase may be greater in some individual subjects, though specific data were not provided. A review article presented additional data from what appears to be the same or a similar study.<sup>2</sup> Based on presented data, the average amitriptyline AUC was 8% higher with concurrent topiramate, and the nortriptyline (active metabolite of amitriptyline) AUC and Cmax were each approximately 20% higher with topiramate.<br><br>The clinical significance of this interaction is uncertain. Both drugs are considered to have CNS depressant effects, suggesting that concurrent use could result in at least additive CNS depression, an effect that could be exaggerated further if concentrations of amitriptyline and/or nortriptyline are elevated with use of the combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Topamax</i> (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2014.</p>\n<p>2. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. <i>Clin Pharmacokinet</i>. 2004;43(12):763-780. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15355124\">[PubMed 15355124]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8411":"<p><b>Title</b> Rilpivirine / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Rilpivirine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase the rilpivirine adult dose to 50 mg daily during concomitant treatment with rifabutin. Decrease the rilpivirine dose back to 25 mg daily following rifabutin discontinuation. If rilpivirine is used as part of the emtricitabine, rilpivirine, tenofovir disoproxil fumarate combination product (Complera) then an additional 25 mg of rilpivirine once per day is recommended for the duration of the rifabutin coadministration. Use of rifabutin with the emtricitabine, rilpivirine, tenofovir alafenamide combination product (Odefsey) is not recommended.</p> \n<p><b>Discussion</b> In a clinical study summarized in rilpivirine US prescribing information, rifabutin (300 mg daily) decreased the rilpivirine (25 mg daily) maximum concentration, minimum concentration, and AUC by 31%, 48%, and 42%, respectively.<sup>1,2,3</sup> When the rilpivirine dose was increased to 50 mg daily and combined with rifabutin, the rilpivirine AUC was only 16% higher than that of rilpivirine 25 mg daily alone.<sup>2</sup><br><br>The suspected primary mechanism of interaction between these agents is rifabutin induction of CYP3A4-mediated rilpivirine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Edurant (rilpivirine) [prescribing information]. Titusville NJ: Janssen Products LP; August 2015.</p>\n<p>2. Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2016.</p>\n<p>3. Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences Inc; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8412":"<p><b>Title</b> Fingolimod / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Fingolimod. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for reduced systemic effects of fingolimod during concomitant treatment with carbamazepine, and for increased effects following carbamazepine discontinuation.</p> \n<p><b>Discussion</b> In a clinical study summarized in fingolimod US prescribing information, coadministration of carbamazepine (600 mg twice daily) decreased the AUC of fingolimod (2 mg single oral dose) and fingolimod-phosphate by roughly 40%.<sup>1</sup> The exact mechanism of this interaction is unclear. The capacity of carbamazepine to induce the major pathway of fingolimod (CYP4F2) has not been characterized, although its capacity to induce at least one minor fingolimod metabolic pathway (CYP3A4) is well-established.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Gilenya</i> (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8413":"<p><b>Title</b> Thiopental / Valerian</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valerian may enhance the CNS depressant effect of Thiopental. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients using valerian or valerian-containing products may experience enhanced or prolonged thiopental effects. Monitor patient clinical response closely.</p> \n<p><b>Discussion</b> According to the thiopental summary of product characteristics, the herbal product valerian may prolong thiopental effects.<sup>1</sup> A study in mice reported an increase in thiopental sleeping time and other evidence of sedative effects following administration of a valerian root extract.<sup>2</sup> The clinical significance of this purported interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Reading, Berkshire, United Kingdom: Archimedes Pharma UK Limited; January 2014.</p>\n<p>2. Leuschner J, Muller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. <i>Arzneimittelforschung</i>. 1993;43(6):638-641. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8352816\">[PubMed 8352816]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8414":"<p><b>Title</b> Thiopental / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may enhance the CNS depressant effect of Thiopental. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients using St Johns wort may experience enhanced or prolonged thiopental effects. Monitor patient clinical response closely.</p> \n<p><b>Discussion</b> According to the thiopental summary of product characteristics, the herbal product St Johns wort may prolong thiopental effects, though no specific data concerning this possible interaction are available.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Reading, Berkshire, United Kingdom: Archimedes Pharma UK Limited; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8415":"<p><b>Title</b> Diazoxide / Thiopental</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiopental may enhance the hypotensive effect of Diazoxide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient hemodynamics extra closely if this combination is used. Particular caution for possible hypotension is warranted.</p> \n<p><b>Discussion</b> According to the thiopental summary of product characteristics, concurrent use of diazoxide may result in a greater risk of a hypotensive effect.<sup>1</sup><br><br>With an intravenous formulation of diazoxide (no longer available), several cases of severe hypotension (at times fatal) have been documented following combined use with hydralazine within a few hours of one another.<sup>2,3,4,5</sup> It is presumed that the vasodilatory effects of the two agents were additive, apparently beyond the ability of the body to maintain adequate pressure.<br><br>Prescribing information for the oral diazoxide formulation (labeled for use as anti-hypoglycemic agent) states that blood pressure-lowering effects of oral diazoxide are relatively minor, particularly as compared to intravenous diazoxide.<sup>6</sup> Despite this reportedly minor hypotensive effect, the prescribing information cautions that oral diazoxide may enhance the blood pressure-lowering effect of antihypertensives.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products Pty Ltd.; September 2013.</p>\n<p>2. Henrich WL, Cronin R, Miller PD, Anderson RJ. Hypotensive sequelae of diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;237(3):264-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576161\">[PubMed 576161]</a></p>\n<p>3. Miller WE, Gifford RW, Humphrey DC, Vidt DG. Management of severe hypertension with intravenous injections of diazoxide. <i>Am J Cardiol</i>. 1969;24(6):870-875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5360241\">[PubMed 5360241]</a></p>\n<p>4. Mizroch S, Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;237(23):2471-2472. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=576958\">[PubMed 576958]</a></p>\n<p>5. Romberg GP, Lordon RE. Hypotensive sequelae of diazoxide and hydralazine therapy. <i>JAMA</i>. 1977;238(10):1025. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=577939\">[PubMed 577939]</a></p>\n<p>6. <i>Proglycem</i> (diazoxide) [prescribing information]. Miami, FL: IVAX Pharmaceuticals, Inc.; October 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8416":"<p><b>Title</b> Thiopental / Ketamine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ketamine may enhance the adverse/toxic effect of Thiopental. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving ketamine together with thiopental may experience a greater risk for hypotension and/or respiratory depression. The risk is likely greater with larger ketamine doses and/or rapid ketamine administration.</p> \n<p><b>Discussion</b> According to the thiopental summary of product characteristics, concurrent use of ketamine (especially higher doses and/or rapid administration) may increase the risk of hypotension or respiratory depression.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thiopental [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products Pty Ltd.; September 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8417":"<p><b>Title</b> CNS Depressants / Kava Kava</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Kava Kava may enhance the adverse/toxic effect of CNS Depressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caution patients about the potential for increased sedation and CNS depressant effects if kava is used with a CNS depressant. Monitor response to concomitant use closely.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> A case report describes a 37 year old man who presented to the emergency department after consumption of kava containing herbal tea with symptoms of altered mental status, confusion, and ataxia.<sup>1</sup> Another case-report describes a 54 year old man receiving alprazolam who developed a lethargic and disoriented state that led to hospitalization three days after taking kava bought at a local health food store.<sup>2</sup> In both cases, the patients' symptoms resolved over several hours. In rats, kava administration resulted in a decrease in amphetamine-induced hypermobility and prolongation of the sleep phase induced by pentobarbital.<sup>3</sup><br><br>It is proposed that kava enhances endogenous ligand binding to gamma-aminobutyric acid (GABA) receptors, which leads to its anxiolytic properties and central nervous system effects. <sup>4,5</sup> Combination with CNS depressants may have additive effects and should only be done with caution.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Perez J, Holmes JF. Altered mental status and ataxia secondary to acute kava ingestion. <i>J Emerg Med</i>. 2005;28(1):49-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15657005\">[PubMed 15657005]</a></p>\n<p>2. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. <i>Ann Intern Med</i>. 1996;125(11):940-941. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8967683\">[PubMed 8967683]</a></p>\n<p>3. Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of kava kava and passiflora extracts combination. <i>Phytomedicine</i>. 2005;12(1-2):39-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15693706\">[PubMed 15693706]</a></p>\n<p>4. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. <i>Drugs</i>. 2009;69(13):1777-1798. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19719333\">[PubMed 19719333]</a></p>\n<p>5. Sarris J. LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. <i>Aust N Z J Psychiatry</i>. 2011;45(1):27-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21073405\">[PubMed 21073405]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8418":"<p><b>Title</b> Adenosine / Caffeine and Caffeine Containing Products</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may diminish the therapeutic effect of Adenosine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Therapeutic effects of adenosine may be significantly blunted by caffeine (and other methylxanthines). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Caffeine (200 mg) ingestion was associated with more than a 50% decrease in the magnitude of adenosine-induced perfusion abnormality in one study of 30 patients undergoing myocardial perfusion scintigraphy with standard dose adenosine (140 mcg/kg/min).<sup>1</sup> Studies with higher dose adenosine (210 mcg/kg/min) were not significantly altered by caffeine. Caffeine infusion antagonized adenosine-mediated increases in blood flow (i.e., vasodilation) by more than 50% in a study using the human forearm (n=6).<sup>2</sup> The methylxanthine theophylline had a similar effect. In a study of 7 healthy volunteers adenosine had a significantly greater impact on systolic blood pressure with longer duration of caffeine abstinence, with a mean -1 mmHg impact on systolic pressure at 6 hours vs. a mean of +9 mmHg at 318 hours of caffeine abstinence; the tachycardia response to adenosine was not similarly affected by caffeine abstinence.<sup>3</sup> Similarly, caffeine antagonized the adenosine-mediated increase in pulse pressure and heart rate observed in 10 normotensive volunteers.<sup>4</sup><br><br>In contrast to these and other studies suggesting the presence of an interaction, some studies have found that caffeine does not significantly alter adenosine imaging results and/or adenosine-mediated change in coronary blood flow.<sup>5,6</sup><br><br>Based on available data, adenosine prescribing information acknowledges that methylxanthines, like caffeine and theophylline, may antagonize the effects of adenosine.<sup>7,8</sup> Consequently, the prescribing information for therapeutic adenosine cautions that higher adenosine doses may be required with concurrent methylxanthines.<sup>7</sup> The prescribing information for diagnostic adenosine recommends that all methylxanthines be withheld for at least 5 half-lives prior to administration of adenosine.<sup>8</sup><br><br>The mechanism for this apparent interaction is thought to be methylxanthine antagonism of at least one specific adenosine receptor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Reyes E, Loong CY, Harbinson M, Donovan J, Anagnostopoulos C, Underwood SR. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. <i>J Am Coll Cardiol</i>. 2008;52(24):2008-2016. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19055993\">[PubMed 19055993]</a></p>\n<p>2. Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. <i>Clin Pharmacol Ther</i>. 1990;48(4):410-418. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225701\">[PubMed 2225701]</a></p>\n<p>3. Rongen GA, Brooks SC, Ando S, Notarius CF, Floras JS. Caffeine abstinence augments the systolic blood pressure response to adenosine in humans. <i>Am J Cardiol</i>. 1998;81(11):1382-1385. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9631984\">[PubMed 9631984]</a></p>\n<p>4. Smits P, Schouten J,PharmD07 Thien T. Cardiovascular effects of two xanthines and the relation to adenosine antagonism. <i>Clin Pharmacol Ther</i>. 1989;45(6):593-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2659234\">[PubMed 2659234]</a></p>\n<p>5. Zoghbi GJ, Htay T, Aqel R, Blackmon L, Heo J, Iskandrian AE. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. <i>J Am Coll Cardiol</i>. 2006;47(11):2296-2302. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16750699\">[PubMed 16750699]</a></p>\n<p>6. Aqel RA, Zoghbi GJ, Trimm JR, Baldwin SA, Iskandrian AE. Effect of caffeine administered intravenously on intracoronary-administered adenosine-induced coronary hemodynamics in patients with coronary artery disease. <i>Am J Cardiol</i>. 2004;93(3):343-346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14759387\">[PubMed 14759387]</a></p>\n<p>7. <i>Adenocard</i> (adenosine) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc; November 2009.</p>\n<p>8. <i>Adenoscan</i> (adenosine) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc; November 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8419":"<p><b>Title</b> Formoterol / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of formoterol (e.g., hypokalemia, blood pressure/heart rate elevation) with concomitant use of caffeine.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Prescribing information for formoterol warns that concomitant treatment with xanthine derivatives may enhance the hypokalemic effects of formoterol.<sup>1</sup> Increased sympathomimetic effects of the agents (e.g., increases in blood pressure, heart rate) would be expected as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dulera</i> (mometasone/formoterol) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co. Inc; June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8420":"<p><b>Title</b> Indacaterol / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Indacaterol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of indacaterol (e.g., hypokalemia, blood pressure/heart rate elevation) with concomitant use of caffeine.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Prescribing information for indacaterol warns that concomitant treatment with xanthine derivatives may enhance the hypokalemic effects of indacaterol.<sup>1</sup> Increased sympathomimetic effects of the agents (e.g., increases in blood pressure, heart rate) would be expected as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Arcapta</i> (indacaterol) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8421":"<p><b>Title</b> Caffeine and Caffeine Containing Products / Norfloxacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Norfloxacin may increase the serum concentration of Caffeine and Caffeine Containing Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Patients should be cautioned regarding the potential increases in caffeine effects that might occur during concomitant therapy with norfloxacin. Depending on the patient's sensitivity to caffeine and the dose of norfloxacin being used, the patient might be encouraged to limit caffeine intake during the course of antibiotic therapy.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> Norfloxacin administration (400 mg twice daily for 4 days) resulted in a small increase (16%) in caffeine AUC (230 mg single dose).<sup>1</sup> In another study, the clearance of a single dose of caffeine (350 mg) was reduced by approximately 35% when coadministered with an 800 mg dose of norfloxacin.<sup>2</sup> The suspected primary mechanism of this interaction is norfloxacin inhibition of CYP1A2 mediated caffeine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-quinolones inhibit biotransformation of caffeine. <i>Eur J Clin Pharmacol</i>. 1988;35(6):651-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2853056\">[PubMed 2853056]</a></p>\n<p>2. Carbo M, Segura J, De la Torre R, Badenas JM, Cami J. Effect of quinolones on caffeine disposition. <i>Clin Pharmacol Ther</i>. 1989;45(3):234-240. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2920498\">[PubMed 2920498]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8422":"<p><b>Title</b> Regadenoson / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may diminish the vasodilatory effect of Regadenoson. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> In a randomized, double blind, study, 207 subjects with coronary artery disease underwent baseline regadenoson stress myocardial perfusion imaging (MPI). Subjects were then randomized to receive 200 mg of caffeine, 400 mg of caffeine, or placebo 90 minutes prior to a repeat MPI. The mean number of coronary artery segments with detectable reversible perfusion defects decreased from the baseline MPI compared to the second MPI in both caffeine groups, while there was no change in the placebo group.<sup>1</sup> The authors suggest that caffeine consumption may adversely affect the diagnostic conclusions of regadenoson MPI. In contrast, caffeine (200mg) administration 2 hours prior to regadenoson had no significant impact on the hyperemic myocardial blood flow response (MBF) or on the calculated coronary flow reserve (ratio of hyperemic MBF to rest MBF) in a study of 41 healthy volunteers.<sup>2</sup> In both studies, heart rate response to regadenoson was blunted by caffeine administration and blood pressure was higher in caffeine treated patients.<sup>1,2</sup><br><br>A study in dogs reported no effect of caffeine (1-10 mg/kg) on regadenoson-induced maximal increase coronary blood flow (CBF).<sup>3</sup> However, caffeine was associated with a dose-dependent decrease (by 17%-82%) in the duration of 2-fold CBF increase, and the highest two caffeine doses were also associated with blunted mean arterial pressure and heart rate responses to regadenoson.<br><br>Regadenoson prescribing information cautions that methylxanthines such as caffeine may impair the vasodilatory effects of regadenoson via non-specific adenosine receptor antagonism and recommends withholding methylxanthine containing products for at least 12 hours prior to regadenoson administration.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tejani FH, Thompson RC, Kristy R, Bukofzer S. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. <i>Int J Cardiovasc Imaging</i>. 2014;30(5):979-989. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24737255\">[PubMed 24737255]</a></p>\n<p>2. Gaemperli O, Schepis T, Koepfli P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography. <i>J Am Coll Cardiol</i>. 2008;51(3):328-329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18206744\">[PubMed 18206744]</a></p>\n<p>3. Zhao G, Messina E, Xu X, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A<sub>2A</sub> receptor agonist. <i>J Cardiovasc Pharmacol</i>. 2007;49(6):369-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17577101\">[PubMed 17577101]</a></p>\n<p>4. <i>Lexiscan</i> (regadenoson) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8423":"<p><b>Title</b> Caffeine and Caffeine Containing Products / Simeprevir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Simeprevir may increase the serum concentration of Caffeine and Caffeine Containing Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> According to the simeprevir prescribing information, the caffeine AUC and maximum serum concentration (Cmax) were an average of 26% and 12% higher, respectively, in subjects (n=16) who were given a single 150 mg dose of caffeine following administration of simeprevir (150 mg/day for 11 days).<sup>1</sup><br><br>The specific mechanism of this apparent interaction is uncertain, but simeprevir is characterized as being a mild inhibitor of CYP1A2,<sup>1</sup> one the enzymes primarily responsible for metabolism of caffeine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Olysio</i> (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8425":"<p><b>Title</b> Caffeine and Caffeine Containing Products / Stiripentol</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Stiripentol may increase the serum concentration of Caffeine and Caffeine Containing Products. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> According to the stiripentol product monograph, patients taking stiripentol should not consume caffeine or caffeine-containing products due to the risk for increased caffeine concentrations and effects.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> The stiripentol product monograph warns that stiripentol may inhibit the metabolism of caffeine, though there are no specific data presented for such concurrent use.<sup>1</sup> Since such an interaction cannot be excluded, however, patients taking stiripentol are cautioned not to consume caffeine or caffeine-containing products. One in vitro study did find that stiripentol inhibited caffeine demethylation, supporting a possible interaction.<sup>2</sup><br><br>The specific mechanism for this possible interaction is most likely stiripentol inhibition of the CYP1A2-mediated metabolism of caffeine, as stiripentol is characterized as an inhibitor of CYP1A2.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Diacomit</i> (stiripentol) [product monograph]. Dundas, Ontario, Canada: C.R.I; December 2013.</p>\n<p>2. Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. <i>Clin Pharmacol Ther</i>. 1997;62(5):490-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9390105\">[PubMed 9390105]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8426":"<p><b>Title</b> Methadone / Benzodiazepines</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Benzodiazepines may enhance the CNS depressant effect of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible, but when the benefits of methadone treatment outweigh the risks associated with the combination, such combined use should only be undertaken with extra caution. The risks associated with long-term use of low-doses is less clear, but any such use should only be considered with a careful evaluation of the potential risks and benefits of such a combination.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> Reports of methadone-related overdoses describe a larger percentage of patients who had evidence of concurrent benzodiazepine use.<sup>1,2,3,4,5</sup> Guidelines for methadone use that focus on methadone safety recommend that concurrent use with benzodiazepines should be generally avoided due to the apparent increase in risk for overdose.<sup>6</sup> A cohort study of 4501 Swedish patients prescribed buprenorphine or methadone for treatment of opioid dependence reported a non-statistically significant increase in overdose-related mortality for patients receiving concurrent benzodiazepines (adjusted HR (adjHR) 1.49 (95% CI 0.97 to 2.29)), along with a significant increase in non-overdose-related mortality (adjHR 2.02 (1.29 to 3.18)).<sup>7</sup> The combination was associated with a significant increase in overdose-related mortality in a sensitivity analysis that was limited to 30 days (vs 90 days) after dispensing of the methadone or buprenorphine (adjHR 1.53). Considering both the potential risks of this combination and the potential risks associated with untreated opioid dependence, a recent FDA safety alert recommends that patients should not be excluded from treatment with methadone for opioid dependence due to concomitant use of CNS depressants.<sup>8</sup><br><br>Whether this interaction is solely a consequence of additive or synergistic CNS depression is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chan GM, Stajic M, Marker EK, Hoffman RS, Nelson LS. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. <i>Acad Emerg Med</i>. 2006;13(5):543-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16641481\">[PubMed 16641481]</a></p>\n<p>2. Gagajewski A, Apple FS. Methadone-related deaths in Hennepin County, Minnesota: 1992-2002. <i>J Forensic Sci</i>. 2003;48(3):668-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12762545\">[PubMed 12762545]</a></p>\n<p>3. Seymour A, Black M, Jay J, Cooper G, Weir C, Oliver J. The role of methadone in drug-related deaths in the west of Scotland. <i>Addiction</i>. 2003;98(7):995-1002. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12814505\">[PubMed 12814505]</a></p>\n<p>4. Sunjic S, Zador D. Methadone-related deaths in New South Wales. <i>Med J Aust</i>. 1997;166(1):54-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9006618\">[PubMed 9006618]</a></p>\n<p>5. Weimer MB, Korthuis PT, Behonick GS, Wunsch MJ. The source of methadone in overdose deaths in Western Virginia in 2004. <i>J Addict Med</i>. 2011;5(3):188-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21844834\">[PubMed 21844834]</a></p>\n<p>6. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. <i>J Pain</i>. 2014;15(4):321-337. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24685458\">[PubMed 24685458]</a></p>\n<p>7. Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. <i>Drug Alcohol Depend</i>. 2017;174:58-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28315808\">[PubMed 28315808]</a></p>\n<p>8. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm575307.htm. Accessed September 21, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8427":"<p><b>Title</b> Caffeine and Caffeine Containing Products / Terbinafine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Terbinafine (Systemic) may increase the serum concentration of Caffeine and Caffeine Containing Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> A study in 8 healthy male volunteers showed that terbinafine (500mg) decreased the clearance of caffeine (3 mg/kg IV) by 20% and increased the half-life of caffeine by approximately 30%.<sup>1</sup> These effects were greater than those seen with ketoconazole (400mg), which exhibited more minor effects on both caffeine clearance (10% decrease) and half-life (15% increase).<br><br>Another study in 12 healthy volunteers evaluated the effect of terbinafine (250 mg single dose or 250 mg x 3 days) on caffeine metabolism.<sup>2</sup> The results of this study suggest that terbinafine has no affect on the activity of CYP1A2, NAT-2, or xanthine oxidase, which are the enzymes that play a major role in the metabolism of caffeine. Given these findings, the degree to which terbinafine interacts with caffeine and the mechanism by which any such interaction occurs are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wahllander A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. <i>Eur J Clin Pharmacol</i>. 1989;37(3):279-283. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2612543\">[PubMed 2612543]</a></p>\n<p>2. Trepanier EF, Nafziger AN, Kearns GL, Kashuba AD, Amsden GW. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2, and xanthine oxidase. <i>J Clin Pharmacol</i>. 1998;38(5):424-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9602954\">[PubMed 9602954]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8428":"<p><b>Title</b> Caffeine and Caffeine Containing Products / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teriflunomide may decrease the serum concentration of Caffeine and Caffeine Containing Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased caffeine effectiveness in patients receiving concurrent teriflunomide. Due to the long half-life of the teriflunomide (2-3 weeks), any interaction could persist for several weeks to months after the last dose of teriflunomide. This interaction is likely of more significance in those that are using caffeine for a therapeutic purpose rather than those who ingest it in a caffeine containing product (eg, coffee, tea, kola nut, etc.)</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> The caffeine AUC and maximum serum concentration (Cmax) were decreased by an average of 55% and 18%, respectively, following repeated doses of teriflunomide.<sup>1</sup><br><br>The specific mechanism for this reported interaction likely involves teriflunomide induction of the CYP1A2-mediated metabolism of caffeine.<sup>1</sup> Due to the long half-life of the teriflunomide (2-3 weeks), any interaction could persist for several weeks to months after the last dose of teriflunomide.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8429":"<p><b>Title</b> Bosentan / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Bosentan. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The bosentan pharmacokinetics were not significantly changed with concurrent St Johns wort in a study of 9 healthy volunteers (all CYP2C9 extensive metabolizers) who received bosentan (125 mg twice daily) with St Johns wort (300 mg three times/day for 10 days).<sup>1</sup> It was noted, however, that there was considerable variability in bosentan pharmacokinetics so a possible clinically relevant interaction in individual patients can not be ruled out.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Markert C, Ngui P, Hellwig R, et al. Influence of St. John's wort on the steady-state pharmacokinetics and metabolism of bosentan. <i>Int J Clin Pharmacol Ther</i>. 2014;52(4):328-336. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24472406\">[PubMed 24472406]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8430":"<p><b>Title</b> Anticoagulants / Vorapaxar</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vorapaxar may enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of vorapaxar in combination with anticoagulants.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Vorapaxar US prescribing information states that its use in combination with anticoagulants should be avoided.<sup>1</sup> Use of anticoagulants is one of several factors expected to increase the risk of bleeding in patients treated with vorapaxar. Other likely risk factors include older age, low body weight, reduced renal function, reduced hepatic function, a history of bleeding disorders, and use of other antiplatelet agents.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zontivity</i> (vorapaxar) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8431":"<p><b>Title</b> BuPROPion / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> St John's Wort may enhance the adverse/toxic effect of BuPROPion. St John's Wort may decrease the serum concentration of BuPROPion. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A case report describes a 58-year-old female who presented with a 2-hour history of oro-facial dystonia that was attributed to the combination of bupropion (150 mg/day, started 4 days prior) and St John's wort (300 mg/day, taken regularly for several years).<sup>1</sup> The dystonia gradually diminished over the subsequent 5 months with several different treatments. One prior published case report described dose-dependent oro-facial dystonia associated with bupropion (at a dose of 150 mg twice/day of the sustained-release product), but this was not deemed to be due to any drug interaction.<sup>2</sup><br><br>The potential mechanism for this dystonia is stimulation of dopaminergic pathways in the CNS by St John's wort-mediated inhibition of serotonin reuptake.<sup>1</sup> Bupropion itself has some direct dopaminergic effects, and may also have some weak inhibition of serotonin reuptake.<sup>1</sup><br><br>The bupropion AUC was an average of 17% lower with concurrent St John's wort in a study of 18 healthy volunteers who received a single dose of buproprion 150 mg (sustained-release) following pretreatment with St John's wort (300 mg three times/day for 14 days).<sup>3</sup> One subject experienced a more dramatic reduction in bupropion AUC, with more than a 50% reduction with concurrent St John's wort. The AUC of the active hydroxybupropion metabolite was an average of 7% lower.<br><br>The likely mechanism for this pharmacokinetic interaction is St John's wort-mediated induction of CYP2B6, resulting in increased metabolism of bupropion. Consistent with this, the oral clearance of bupropion was increased by an average of 20% with St John's wort.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Milton JC, Abdulla A. Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's Wort. <i>Br J Clin Pharmacol</i>. 2007;64(5):717-718. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17578477\">[PubMed 17578477]</a></p>\n<p>2. Detweiler MB, Harpold GJ. Bupropion-induced acute dystonia. <i>Ann Pharmacother</i>. 2002;36(2):251-254. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11847943\">[PubMed 11847943]</a></p>\n<p>3. Lei HP, Yu XY, Xie HT, et al. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. <i>Xenobiotica</i>. 2010;40(4):275-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20102294\">[PubMed 20102294]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8432":"<p><b>Title</b> Vorapaxar / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vorapaxar. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of vorapaxar in combination with strong CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic)*, Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministration of ketoconazole (400 mg orally daily for 28 days) increased the vorapaxar (20 mg orally on day 7, then 2.5 mg orally daily) first-dose and final-dose AUCs by 23% and 96%, respectively.<sup>1,2</sup> The vorapaxar final-dose maximum plasma concentration was also increased by 93%. The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A mediated vorapaxar metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zontivity</i> (vorapaxar) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2014.</p>\n<p>2. Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. <i>J Clin Pharmacol</i>. 2013;53(5):540-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23426761\">[PubMed 23426761]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8433":"<p><b>Title</b> Vorapaxar / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of vorapaxar in combination with strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministration of rifampin (600 mg orally daily for 28 days) decreased the vorapaxar (20 mg orally on day 7, then 2.5 mg orally daily) final-dose maximum plasma concentration (Cmax) and AUC, by 39% and 55%, respectively.<sup>1,2</sup> Vorapaxar first-dose Cmax and AUC were unaffected. The suspected primary mechanism of this interaction is rifampin induction of CYP3A mediated vorapaxar metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zontivity</i> (vorapaxar) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2014.</p>\n<p>2. Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. <i>J Clin Pharmacol</i>. 2013;53(5):540-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23426761\">[PubMed 23426761]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8434":"<p><b>Title</b> OXcarbazepine / Eslicarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Eslicarbazepine may enhance the adverse/toxic effect of OXcarbazepine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The eslicarbazepine prescribing information warns not to use eslicarbazepine as an adjunct to oxcarbazepine.</p> \n<p><b>Discussion</b> The eslicarbazepine prescribing information warns not to use eslicarbazepine as an adjunct to oxcarbazepine.<sup>1</sup> Specific details supporting this warning are not provided, but oxcarbazepine is structurally similar to eslicarbazepine and is a minor active metabolite of eslicarbazepine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptiom</i> (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8435":"<p><b>Title</b> FentaNYL / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of FentaNYL. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of reduced analgesic effects and/or emergence of possible withdrawal signs/symptoms if fentanyl is used together with St John's wort, particularly if St John's wort is initiated in a patient previously stable on fentanyl. Caution is also warranted if a patient who had been maintained on this combination discontinues St John's wort, as fentanyl concentrations and effects would be expected to increase as the inducing effects of St John's wort diminish.</p> \n<p><b>Discussion</b> The fentanyl prescribing information cautions that drugs capable of inducing CYP3A4 may decrease fentanyl concentrations and effects, possibly also increasing the risk for withdrawal signs and symptoms.<sup>1,2</sup> Specific data with St John's wort are not available, but a study of the CYP3A inducer rifampin found that the fentanyl AUC was an average of 63% lower with concurrent rifampin.<sup>3</sup> Published case reports describe reduced fentanyl effectiveness in patients who were treated with rifampin.<sup>4,5</sup><br><br>The likely mechanism for this potential interaction is enhanced fentanyl metabolism by St John's wort-mediated induction of CYP3A, leading to reduced fentanyl serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Duragesic</i> (fentanyl) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Actiq</i> (fentanyl) [prescribing information]. Frazer, PA: Cephalon, Inc.; June 2012.</p>\n<p>3. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. <i>Anesthesiology</i>. 2004;101(3):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15329598\">[PubMed 15329598]</a></p>\n<p>4. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I. Rifampin reduces the analgesic effect of transdermal fentanyl. <i>Ann Pharmacother</i>. 2005;39(12):2139-2140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16288064\">[PubMed 16288064]</a></p>\n<p>5. Morii H, Chiba M, Konishi H, Endo Y, Yamaji A. Failure of pain control using transdermal fentanyl during rifampicin treatment. <i>J Pain Symptom Manage</i>. 2007;33(1):5-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17196900\">[PubMed 17196900]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8436":"<p><b>Title</b> FentaNYL / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of reduced analgesic effects and/or emergence of possible withdrawal signs/symptoms if fentanyl is used together with a strong CYP3A4 inducer, particularly if the CYP3A4 inducer is initiated in a patient previously stable on fentanyl. Caution is also warranted if a patient who had been maintained on this combination discontinues the strong CYP3A4 inducer, as fentanyl concentrations and effects would be expected to increase as the effect of the CYP3A4 inducer diminishes.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The fentanyl prescribing information cautions that drugs capable of inducing CYP3A4 may decrease fentanyl concentrations and effects, possibly also increasing the risk for withdrawal signs and symptoms.<sup>1,2</sup> Specific data with such agents are limited, but a study of the CYP3A inducer rifampin found that the fentanyl AUC was an average of 63% lower with concurrent rifampin.<sup>3</sup> Published case reports describe reduced fentanyl effectiveness in patients who were treated with rifampin.<sup>4,5</sup><br><br>The likely mechanism for this potential interaction is enhanced fentanyl metabolism due to induction of CYP3A, leading to reduced fentanyl serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Duragesic</i> (fentanyl) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Actiq</i> (fentanyl) [prescribing information]. Frazer, PA: Cephalon, Inc.; June 2012.</p>\n<p>3. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. <i>Anesthesiology</i>. 2004;101(3):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15329598\">[PubMed 15329598]</a></p>\n<p>4. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I. Rifampin reduces the analgesic effect of transdermal fentanyl. <i>Ann Pharmacother</i>. 2005;39(12):2139-2140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16288064\">[PubMed 16288064]</a></p>\n<p>5. Morii H, Chiba M, Konishi H, Endo Y, Yamaji A. Failure of pain control using transdermal fentanyl during rifampicin treatment. <i>J Pain Symptom Manage</i>. 2007;33(1):5-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17196900\">[PubMed 17196900]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8437":"<p><b>Title</b> Riociguat / Roflumilast</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Roflumilast may enhance the hypotensive effect of Riociguat. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with nonselective phosphodiesterase inhibitors or phosphodiesterase type 5 inhibitors is contraindicated due to the risk of hypotension. While other phosphodiesterase inhibitors, such as roflumilast, are not specifically contraindicated with riociguat, concomitant use should be undertaken with caution and patients should be monitored for the development of hypotension.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with pulmonary arterial hypertension who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1 to 2.5 mg 3 times/day together with sildenafil (20 mg 3 times/day), one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination. No clinical studies have been conducted with riociguat and other types of phosphodiesterase inhibitors so the combined effect on blood pressure is unknown.<br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cyclic nucleotides that result in vasodilation such as cGMP or cAMP, resulting in possible additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adempas</i> (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8438":"<p><b>Title</b> Pramipexole / CISplatin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CISplatin may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters.<sup>1,2</sup> The results from a population study described in the product label show that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, MorikawaM, Igarashi T, Tamai I. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8439":"<p><b>Title</b> Pramipexole / Procainamide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Procainamide may increase the serum concentration of Pramipexole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Pramipexole prescribing information cautions that drugs that are substrates or inhibitors of cationic transport systems (specific agents listed in prescribing information include cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, quinine, cisplatin, and procainamide) may interfere with the elimination of pramipexole, which is also a substrate for cationic transporters.<sup>1,2</sup> The results from a population study described in the product label show that concurrent use with such drugs was associated with an average 20% decrease in pramipexole oral clearance.<sup>1</sup> The extent to which such a decrease in clearance would impact serum concentrations/AUC and/or be of clinical significance is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Mirapex ER</i> (pramipexole) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; May 2014.</p>\n<p>2. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. <i>Drug Metab Dispos</i>. 2005;33(4):495-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15640376\">[PubMed 15640376]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8440":"<p><b>Title</b> Cardiac Glycosides / Licorice</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Licorice may enhance the adverse/toxic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased toxic effects of cardiac glycosides if licorice is used concomitantly. Evaluation of serum potassium may be warranted.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> The risk of digitalis toxicity increases in the presence of hypokalemia and digoxin prescribing information recommends careful monitoring of serum potassium levels when digoxin is given to patients at risk for hypokalemia.<sup>1</sup> Several case reports have described severe hypokalemia associated with licorice consumption.<sup>2,3,4,5</sup> While the amount of licorice needed to induce hypokalemia is unknown, careful monitoring of serum potassium along with monitoring for signs and symptoms of digoxin toxicity are likely warranted if combined with digoxin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012.</p>\n<p>2. Yorgun H, Aksoy H, Sendur MA, et al. Brugada syndrome with aborted sudden cardiac death related to liquorice-induced hypokalemia. <i>Med Princ Pract</i>. 2010;19(6):485-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20881418\">[PubMed 20881418]</a></p>\n<p>3. Pant P, Nadimpalli L, Singh M, Cheng JC. A case of severe hypokalemic paralysis and hypertension. Licorice-induced hypokalemic paralysis. <i>Am J Kidney Dis</i>. 2010;55(6):A35-A37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20497832\">[PubMed 20497832]</a></p>\n<p>4. Murphy SC, Agger S, Rainey PM. Too much of a good thing: a woman with hypertension and hypokalemia. <i>Clin Chem</i>. 2009;55(12):2093-2096. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19946064\">[PubMed 19946064]</a></p>\n<p>5. Francini-Pesenti F, Puato M, Piccoli A, Brocadello F. Liquorice-induced hypokalemia and water retention in the absence of hypertension. <i>Phytother Res</i>. 2008;22(4):563-565. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18386259\">[PubMed 18386259]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8441":"<p><b>Title</b> Serotonin Modulators / Antiemetics (5HT3 Antagonists)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of agents that enhance serotonin activity should be undertaken with caution due to the risk of serotonin syndrome. The labeling for 5HT3 antagonists warns of the risk of serotonin syndrome when 5HT3 antagonists are combined with other serotonergic medications and cautions that patients should be monitored for the development of serotonin syndrome during such therapy.</p>\n<div>\n <p><b>Antiemetics (5HT3 Antagonists) Interacting Members</b> Alosetron, Dolasetron, Granisetron, Ondansetron, Palonosetron, Ramosetron, Tropisetron</p>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> Three case reports describe the development of serotonin syndrome/serotonin toxicity (SS/ST) in the perioperative period in patients who received ondansetron prior to the end of anesthesia.<sup>1,2,3,4</sup> In all three cases, the patients also received multiple additional serotonergic medications. In the first case, duloxetine, lithium, and fentanyl were co-administered with ondansetron.<sup>1</sup> In the second case, paroxetine and methylene blue were potential contributing factors.<sup>2,3</sup> In the third case, paroxetine, duloxetine, and fentanyl were also given to the patient.<sup>4</sup> The development of SS/ST was also reported in a 12 year old boy on mirtazapine after being given ondansetron.<sup>5</sup> The occurrence of SS/ST from the use of serotonergic drugs with granisetron and dolasetron has also been published, although the symptomatology described in the reports makes a definitive diagnosis uncertain.<sup>5,6</sup> While most reports describe the development of SS/ST due to the combination of numerous serotonergic agents, toxicities with ondansetron alone were reported in an infant following an ondansetron overdose<sup>7</sup> and in a 5 year old boy with a genetic predisposition for malignant hyperthermia.<sup>8</sup><br><br>Although reports of this interaction are limited, due to the severity of serotonin syndrome and the inability to rule out the contributory role of these medications, US and Canadian product labeling for 5HT3 antagonists now warns that serotonin syndrome can occur when these agents are combined with other serotonergic drugs.<br><br>Although not completely understood, there is a proposed mechanism for the potential increased vulnerability to serotonin syndrome when concomitantly using 5HT3 antagonists and other serotonergic drugs. Blocking the 5-HT3 receptor subtype effectively increases levels of available serotonin. This excessive serotonin is then able to stimulate other serotonin receptor subtypes, particularly 5HT2A, the receptor type thought to contribute substantially to the condition.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Altman CS, Jahangiri MF. Serotonin syndrome in the perioperative period. <i>Anesth Analg</i>. 2010;110(2):526-528. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19955502\">[PubMed 19955502]</a></p>\n<p>2. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? <i>J Psychopharmacol</i> 1999;13(3):313-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10512094\">[PubMed 10512094]</a></p>\n<p>3. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. <i>J Psychopharmacol</i>. 2010;24(10):1433-1438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19423610\">[PubMed 19423610]</a></p>\n<p>4. Gollapudy S, Kumar V, Dhamee MS. A case of serotonin syndrome precipitated by fentanyl and ondansetron in a patient receiving paroxetine, duloxetine, and bupropion. <i>J Clin Anesth</i>. 2012;24(3):251-252. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22537574\">[PubMed 22537574]</a></p>\n<p>5. Turkel SB, Nadala JG, Wincor MZ. Possible serotonin syndrome in association with 5-HT(3) antagonist agents. <i>Psychosomatics</i>. 2001;42(3):258-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11351116\">[PubMed 11351116]</a></p>\n<p>6. Sorscher SM. Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist. <i>J Psychopharmacol</i>. 2002;16(2):191. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12095081\">[PubMed 12095081]</a></p>\n<p>7. George M, Al-Duaij N, O’Donnell KA, Shannon MW. Obtundation and seizure following ondansetron overdose in an infant. <i>Clin Toxicol (Phila)</i>. 2008;46(10):1064-1066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18803119\">[PubMed 18803119]</a></p>\n<p>8. Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. <i>Pediatrics</i>. 2010;125(6):e1514-e1517. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20439600\">[PubMed 20439600]</a></p>\n<p>9. Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15784664\">[PubMed 15784664]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8442":"<p><b>Title</b> AbobotulinumtoxinA / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor more closely for signs/symptoms of anticholinergic side effects (e.g., dry mouth, dry eyes, etc.) in patients receiving both abobotulinumtoxin A and anticholinergic agents. Advise patients that the risk for such adverse events may be increased with the combined use of these agents.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> AbobotulinumtoxinA prescribing information cautions that concurrent use of other anticholinergic drugs may increase the risk for anticholinergic adverse effects of abobotulinumtoxinA therapy.<sup>1</sup> The extent to which other botulinum toxins share this interaction is uncertain, but considering that all agents prevent the release of acetylcholine from presynaptic nerve terminals suggests that this interaction would be possible with all such agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dysport</i> (abobotulinumtoxinA) [prescribing information]. Scottsdale, AZ: Medicis Aesthetics Inc; May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8443":"<p><b>Title</b> Cannabinoid-Containing Products / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor cardiovascular status closely if a cannabinoid and an anticholinergic agent must be used together.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n <p><b>Cannabinoid-Containing Products Interacting Members</b> Cannabis, Dronabinol, Nabilone, Tetrahydrocannabinol<br><b>Exception</b> Cannabidiol</p>\n</div> \n<p><b>Discussion</b> It has been reported in product labeling that drugs with anticholinergic effects may cause excessive tachycardia and/or hypertension when combined with a cannabinoid.<sup>1</sup> Little independent data exist regarding the validity or significance of this possible interaction. In one study, heart rates after administration of an anticholinergic (atropine) were significantly greater following 14 days of delta-9-tetrahydrocannabinol (THC) than at baseline.<sup>2</sup> Further, following THC treatment, atropine demonstrated a substantial hypertensive effect. Both of these findings offer some support for the validity of such an interaction.<br><br>Cannabinoids are known to cause tachycardia and hypotension independent of any effects of anticholinergic agents.<sup>3</sup> Data showing that the cholinergic agent physostigmine was able to decrease THC-induced tachycardia suggest that cholinergic signaling may play a role in the effects of cannabinoids on heart rate.<sup>4</sup> Whether the cardiovascular effects suspected with the combination of cannabinoids and anticholinergic agents represent additive anticholinergic effects, a distinct direct effect of cannabinoids together with decreased vagal influence, or some combination thereof is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Cesamet</i> (nabilone) [product monograph]. Quebec, Canada: Valeant Canada Ltd; December 2009.</p>\n<p>2. Benowitz NL,Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. <i>Clin Pharmacol Ther</i>. 1977;21(3):336-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=837652\">[PubMed 837652]</a></p>\n<p>3. Williamson EM, Evans FJ. Cannabinoids in clinical practice. <i>Drugs</i>. 2000;60(6):1303-1314. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11152013\">[PubMed 11152013]</a></p>\n<p>4. Freemon FR, Rosenblatt JE, El-Yousef MK. Interaction of physostigmine and delta-9-tetrahydrocannabinol in man. <i>Clin Pharmacol Ther</i>. 1975;17(2):121-6. [PubMed1091392]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8444":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for an increased response to thiazide diuretics during concomitant treatment with an anticholinergic agent, particularly when anticholinergic doses are sufficient to reduce gastrointestinal motility.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Canadian and United Kingdom labeling for some thiazide diuretic containing products warns that coadministration of a thiazide diuretic with an anticholinergic agent may increase bioavailability of the thiazide, potentially necessitating dose adjustment.<sup>1,2</sup> In a clinical study of 6 healthy volunteers, coadministration of propantheline (15 mg orally) 1 h prior to hydrochlorothiazide (75 mg single oral dose) delayed the time to reach maximal hydrochlorothiazide plasma concentration from 2.4 h to 4.8 h, increased the total hydrochlorothiazide AUC in the first 12 hours after dosing by 23%, and increased the total urinary recovery of hydrochlorothiazide in the first 48 hours after dosing by 36%.<sup>3</sup><br><br>The suspected primary mechanism of the described interaction is propantheline enhancement of hydrochlorothiazide bioavailability, and delay of its absorption, via slowing of gastrointestinal motility. Other anticholinergic agents capable of slowing motility could theoretically exert similar effects on most thiazides; coadministration of anticholinergic agents with some thiazide and thiazide-like diuretics that have high estimated bioavailability under normal circumstances, such as bendroflumethiazide and indapamide,<sup>4</sup> may not alter the diuretic's bioavailability substantially but could still alter some other pharmacokinetic properties including the time to reach maximal plasma concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Inhibace Plus</i> (cilazapril and hydrochlorothiazide) [product monograph]. Mississauga, ON: Hoffmann-La Roche Limited; June 2013.</p>\n<p>2. <i>Hygroton</i> (chlorothiazide) [summary of product characteristics]. Wiltshire, UK: Alliance Pharmaceuticals; February 2004.</p>\n<p>3. Beermann B, Groschinsky-Grind M. Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline. <i>Eur J Clin Pharmacol</i>. 1978;13(5):385-387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=668798\">[PubMed 668798]</a></p>\n<p>4. Ernst ME, Moser M. Use of diuretics in patients with hypertension. <i>N Engl J Med</i>. 2009;361(22):2153-2164. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19940300\">[PubMed 19940300]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8445":"<p><b>Title</b> Mirabegron / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Closely monitor patients for signs/symptoms of urinary retention if mirabegron is used in combination with an anticholinergic to treat overactive bladder.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Episodes of urinary retention have been reported in patients treated with both mirabegron and an anticholinergic drug for overactive bladder.<sup>1</sup> Caution should be used during any combination therapy with mirabegron and anticholinergics used to treat overactive bladder due to a risk for urinary retention. Anticholinergics are known to decrease bladder detrusor muscle contraction, which can cause urinary retention.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myrbetriq</i> (mirabegron extended-release) [prescribing information]. Northbrook, IL: Astellas Pharm US Inc; June 2012.</p>\n<p>2. Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. <i>Am Fam Physician</i>. 2008;77(5):643-650. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18350762\">[PubMed 18350762]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8446":"<p><b>Title</b> OnabotulinumtoxinA / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor more closely for signs/symptoms of anticholinergic side effects (e.g., dry mouth, dry eyes, etc.) in patients receiving both onabotulinumtoxin A and anticholinergic agents. Advise patients that the risk for such adverse events may be increased with the combined use of these agents.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> AbobotulinumtoxinA prescribing information cautions that concurrent use of other anticholinergic drugs may increase the risk for anticholinergic adverse effects of abobotulinumtoxinA therapy.<sup>1</sup> The extent to which other botulinum toxins (e.g., onabotulinumtoxinA) share this interaction is uncertain, but considering that all agents prevent the release of acetylcholine from presynaptic nerve terminals suggests that this interaction would be possible with all such agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dysport</i> (abobotulinumtoxinA). Scottsdale, AZ: Medicis Aesthetics Inc; May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8447":"<p><b>Title</b> Potassium Chloride / Anticholinergic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction specifically applies to solid oral dosage forms of potassium chloride.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Agents with greater anticholinergic effects are likely of more concern than agents with lesser anticholinergic effects. Liquid or effervescent potassium preparations are possible alternatives.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics) due to the risks of gastric and intestinal irritation and ulceration associated with prolonged contact between these solid dosage forms and the gastrointestinal mucosa. One publication described an increased frequency and severity of gastrointestinal lesions following both wax-matrix and microencapsulated potassium chloride products amongst patients with slowed gastrointestinal motility due to the effects of anticholinergic drugs.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McMahon FG, Ryan JR, Akdamar K, Ertan A. Effect of potassium chloride supplements on upper gastrointestinal mucosa. <i>Clin Pharmacol Ther</i>. 1984;35(6):852-855. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734038\">[PubMed 6734038]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8448":"<p><b>Title</b> RimabotulinumtoxinB / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor more closely for signs/symptoms of anticholinergic side effects (e.g., dry mouth, dry eyes, etc.) in patients receiving both rimabotulinumtoxinB and anticholinergic agents. Advise patients that the risk for such adverse events may be increased with the combined use of these agents.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> AbobotulinumtoxinA prescribing information cautions that concurrent use of other anticholinergic drugs may increase the risk for anticholinergic adverse effects of abobotulinumtoxinA therapy.<sup>1</sup> The extent to which other botulinum toxins (e.g., rimabotulinumtoxinB) share this interaction is uncertain, but considering that all agents prevent the release of acetylcholine from presynaptic nerve terminals suggests that this interaction would be possible with all such agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dysport</i> (abobotulinumtoxinA) [prescribing information]. Scottsdale, AZ: Medicis Aesthetics Inc; May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8449":"<p><b>Title</b> Secretin / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Anticholinergic Agents may diminish the therapeutic effect of Secretin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Data from human volunteers and animal studies show that cholinergic pathways are involved in determining the response to secretin.<sup>1,2,3,4</sup> These studies have demonstrated that stimulation of cholinergic receptors (with electrical stimulation or use of cholinergic agonists, such as bethanechol) increases the response to secretin.<sup>1,3</sup> Conversely, anticholinergic drugs (ie, atropine) significantly decrease the effects of secretin.<sup>2,3,4</sup> While the effects of other anticholinergic drugs (or drugs with anticholinergic side effects) on secretin response is unknown, it is possible that such agents will similarly decrease the response to secretin.<br><br>Secretin prescribing information states that concomitant use of anticholinergic drugs may cause a hyporesponse to secretin stimulation testing and should be avoided.<sup>5</sup> Discontinue any anticholinergic agents at least 5 half-lives prior to secretin administration.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Valenzuela JE, Weiner K, Saad C. Cholinergic stimulation of human pancreatic secretion. <i>Dig Dis Sci</i>. 1986;31(6):615-619. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872022\">[PubMed 2872022]</a> </p>\n<p>2. Kuvshinoff BW, Demar AR, James L, McFadden DW, Fink AS. Effect of pancreatic denervation and atropine on the pancreatic response to secretin. <i>Pancreas</i>. 1993;8(5):609-614. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8302798\">[PubMed 8302798]</a> </p>\n<p>3. Park HS, Lee YL, Kwon HY, Chey WY, Park HJ. Significant cholinergic role in secretin-stimulated exocrine secretion in isolated rat pancreas. <i>Am J Physiol</i>. 1998;274(2 pt 1):G413-G418. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9486197\">[PubMed 9486197]</a> </p>\n<p>4. Chey WY, Chang TM. Neural control of the release and action of secretin. <i>J Physiol Pharmacol</i>. 2003;54(suppl 4):105-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15075453\">[PubMed 15075453]</a></p>\n<p>5. Chirhostim (secretin) [prescribing information]. Burtonsville, MD: ChiRhoClin, Inc; July 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8450":"<p><b>Title</b> Topiramate / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use these combinations with caution, and advise patients to monitor for reduced sweating and elevated body temperature during physical activity, particularly in hot weather.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> US prescribing information for topiramate products warns that topiramate should be used with caution in combination with other drugs that may predispose to heat-related disorders, including anticholinergic drugs.<sup>1,2</sup> Combining these agents is expected to increase the risk of hyperthermia, due to the independent effects of the drugs on sweating and temperature regulation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Topamax</i> (topiramate) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2011.</p>\n<p>2. <i>Qsymia</i> (phentermine/topiramate) [prescribing information]. Mountain View, CA: Vivus Inc; July 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8451":"<p><b>Title</b> PAZOPanib / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of proton pump inhibitors in combination with pazopanib.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole*, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 12 adult patients with advanced solid tumors, coadministration of esomeprazole (40 mg daily in the evening for 4 days, starting on pazopanib day 7) decreased the median maximum plasma concentration (Cmax), median minimum plasma concentration, and average AUC of pazopanib (800 mg daily in the morning for 12 days) by 42%, 37%, and 40%, respectively (comparing day 7 pharmacokinetic variables to day 12).<sup>1,2</sup> The Cmax and AUC of 3 metabolites were also decreased by 30% to 49%.<br><br>Pazopanib is very slightly soluble at pH 1 and practically insoluble at pH 4.<sup>2,3</sup> Therefore, its use in combination with agents that increase gastric pH may decrease its absorption. Based on the above clinical results, Canadian and US pazopanib labeling recommends avoiding its use in combination with drugs that increase gastric pH.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. <i>Cancer Chemother Pharmacol</i>. 2013;71(6):1635-1643. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23636448\">[PubMed 23636448]</a></p>\n<p>2. <i>Votrient</i> (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</p>\n<p>3. <i>Votrient</i> (pazopanib) [product monograph]. Mississauga, ON: GlaxoSmithKline Inc; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8452":"<p><b>Title</b> PAZOPanib / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of antacids in combination with pazopanib whenever possible. Separate doses by several hours if antacid treatment is considered necessary. The impact of dose separation has not been investigated.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 12 adult patients with advanced solid tumors, coadministration of esomeprazole (40 mg daily in the evening for 4 days, starting on pazopanib day 7) decreased the median maximum plasma concentration (Cmax), median minimum plasma concentration, and average AUC of pazopanib (800 mg daily in the morning for 12 days) by 42%, 37%, and 40%, respectively (comparing day 7 pharmacokinetic variables to day 12).<sup>1,2</sup> The Cmax and AUC of 3 metabolites were also decreased by 30%-49%.<br><br>Pazopanib is very slightly soluble at pH 1 and practically insoluble at pH 4.<sup>2,3</sup> Therefore, its use in combination with agents that increase gastric pH may decrease its absorption. Based on the above clinical results, Canadian and US pazopanib labeling recommends avoiding its use in combination with drugs that increase gastric pH.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. <i>Cancer Chemother Pharmacol</i>. 2013;71(6):1635-1643. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23636448\">[PubMed 23636448]</a></p>\n<p>2. <i>Votrient</i> (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</p>\n<p>3. <i>Votrient</i> (pazopanib) [product monograph]. Mississauga, ON: GlaxoSmithKline Inc; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8453":"<p><b>Title</b> PAZOPanib / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of histamine H2-antagonists in combination with pazopanib. Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 12 adult patients with advanced solid tumors, coadministration of esomeprazole (40 mg daily in the evening for 4 days, starting on pazopanib day 7) decreased the median maximum plasma concentration (Cmax), median minimum plasma concentration, and average AUC of pazopanib (800 mg daily in the morning for 12 days) by 42%, 37%, and 40%, respectively (comparing day 7 pharmacokinetic variables to day 12).<sup>1,2</sup> The Cmax and AUC of 3 metabolites were also decreased by 30%-49%.<br><br>Pazopanib is very slightly soluble at pH 1 and practically insoluble at pH 4.<sup>2,3</sup> Therefore, its use in combination with agents that increase gastric pH may decrease its absorption. Based on the above clinical results, Canadian and US pazopanib labeling recommends avoiding its use in combination with drugs that increase gastric pH.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. <i>Cancer Chemother Pharmacol</i>. 2013;71(6):1635-1643. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23636448\">[PubMed 23636448]</a></p>\n<p>2. <i>Votrient</i> (pazopanib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2014.</p>\n<p>3. <i>Votrient</i> (pazopanib) [product monograph]. Mississauga, ON: GlaxoSmithKline Inc; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8454":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> A single published case report describes a 56 year old man who developed hypertension (blood pressures exceeding 200/110 mmHg) and headaches following an increase in tranylcypromine dose to 50 mg twice daily.<sup>1</sup> The patient consumed 10-12 cups of caffeinated coffee daily. Other medications were not clearly described in the report, except that the patient also took hydrochlorothiazide (25 mg daily). When the patient switched from caffeinated coffee to decaffeinated coffee, while maintaining traylcypromine at the same dose, his blood pressure decreased to 132/66 mmHg.<br><br>It is unclear whether the blood pressure changes in the above report were due to an interaction between caffeine and tranylcypromine. Given the large number of other unknown and potential contributory factors (eg, other dietary choices, tyramine content of the specific coffee consumed), the lack of clear mechanism of interaction between these agents, and the presumably vast clinical record of patients who have taken monoamine oxidase inhibitors and also consumed caffeine (without any such previous reports), among other factors, no general added caution with this combination appears to be justified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. van der Hoeven N, Visser I, Schene A, van den Born BJ. Severe hypertension related to caffeinated coffee and tranylcypromine: a case report. <i>Ann Intern Med</i>. 2014;160(9):657-658. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24798537\">[PubMed 24798537]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8455":"<p><b>Title</b> Pipamperone [INT] / Cabergoline</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of warning associated with this interaction varies according to the country in which the pipamperone product is approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cabergoline may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Cabergoline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of pipamperone and cabergoline. Labeling for some but not all pipamperone products specifically states that this combination is contraindicated.</p> \n<p><b>Discussion</b> According to the summaries of product characteristics for at least some pipamperone products, its combination with the dopamine agonists cabergoline or quinagolide is considered contraindicated.<sup>1</sup> Product labeling in some countries, however, does not specifically mention avoidance of the combination.<sup>2,3</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and pipamperone (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Issy-les-Moulineaux, France: Janssen- Cilag; June 2013.</p>\n<p>2. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Sollentuna, Sweden: Janssen- Cilag; December 2011.</p>\n<p>3. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Tilburg, Netherlands: Janssen-Cilag; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8456":"<p><b>Title</b> Quinagolide / Pipamperone [INT]</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of warning associated with this interaction varies according to the country in which the pipamperone product is approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pipamperone [INT] may diminish the therapeutic effect of Quinagolide. Quinagolide may diminish the therapeutic effect of Pipamperone [INT]. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of pipamperone and quinagolide. Labeling for some but not all pipamperone products specifically states that this combination is contraindicated.</p> \n<p><b>Discussion</b> According to the summaries of product characteristics for at least some pipamperone products, its combination with the dopamine agonists cabergoline or quinagolide is considered contraindicated.<sup>1</sup> Product labeling in some countries, however, does not specifically mention avoidance of the combination.<sup>2,3</sup><br><br>The concern with the combination is that cabergoline or quinagolide (dopamine receptor agonists) and pipamperone (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Sollentuna, Sweden: Janssen- Cilag; December 2011.</p>\n<p>2. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Issy-les-Moulineaux, France: Janssen- Cilag; June 2013.</p>\n<p>3. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Tilburg, Netherlands: Janssen-Cilag; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8457":"<p><b>Title</b> Alcohol (Ethyl) / Pipamperone [INT]</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The strength of warning associated with this interaction varies according to the country in which the pipamperone product is approved and marketed.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Pipamperone [INT] may enhance the adverse/toxic effect of Alcohol (Ethyl). Specifically, sedative and psychomotor effects may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid concurrent use of pipamperone and alcohol. Any combined use can be expected to enhance the sedative and psychomotor effects of both drugs.</p> \n<p><b>Discussion</b> According to the labeling for at least some pipamperone products, concurrent use with alcohol is not recommended and should be avoided or strongly discouraged.<sup>1,2</sup> The concern with the combination is that the sedative and psychomotor effects of both agents may be enhanced. Product labeling in some countries may acknowledge this risk without specifically advising avoidance of the combination.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Sollentuna, Sweden: Janssen- Cilag; December 2011.</p>\n<p>2. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Issy-les-Moulineaux, France: Janssen- Cilag; June 2013.</p>\n<p>3. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Tilburg, Netherlands: Janssen-Cilag; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8458":"<p><b>Title</b> Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) / Pipamperone [INT]</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pipamperone [INT] may diminish the therapeutic effect of Anti-Parkinson Agents (Monoamine Oxidase Inhibitor). Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) may diminish the therapeutic effect of Pipamperone [INT]. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring patients receiving pipamperone in combination with a monoamine oxidase inhibitor anti-Parkinson agent for reduced effects of both agents.</p>\n<div>\n <p><b>Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) Interacting Members</b> Rasagiline, Safinamide, Selegiline</p>\n</div> \n<p><b>Discussion</b> Monoamine oxidase inhibitor anti-Parkinson agents (which act at least in part by inhibiting degradation of dopamine) and pipamperone (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.<sup>1</sup> Patients receiving these combination should therefore be monitored closely for reduced effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Issy-les-Moulineaux, France: Janssen- Cilag; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8459":"<p><b>Title</b> Iodinated Contrast Agents / Aldesleukin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aldesleukin may enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased risk of delayed hypersensitivity reactions if iodinated contrast media is administered to patients who have received aldesleukin.</p>\n<div>\n <p><b>Iodinated Contrast Agents Interacting Members</b> Diatrizoate Meglumine, Diatrizoate Sodium, Ethiodized Oil, Iobitridol, Iodipamide Meglumine, Iodixanol, Iohexol, Iomeprol, Iopamidol, Iopromide, Iothalamate Meglumine, Ioversol, Ioxaglate Meglumine and Ioxaglate Sodium, Ioxitalamate Meglumine, Meglumine Iotroxate</p>\n</div> \n<p><b>Discussion</b> A study described in the aldesleukin prescribing information reported that of 501 patients treated with interleukin-2 (IL-2) therapy who were subsequently administered iodinated contrast media, 12.6% experienced adverse reactions that included fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria. Most reactions occurred 1 to 4 hours after iodinated contrast media administration. The majority of events occurred when the iodinated contrast media was given within 4 weeks of the last IL-2 dose, but some reports occurred several months after IL-2 treatment.<sup>1</sup> Another prospective study compared the incidence of delayed hypersensitivity reactions following iodinated contrast media administration in patients who received IL-2 therapy (n=170) to patients who did not receive IL-2 therapy (n=631).<sup>2</sup> Delayed reactions (eg, fever, rash, flu-like symptoms, joint pain, flushing, pruritus, and dizziness) were reported in 11.8% of IL-2 patients compared to 3.9% of non-IL-2 patients (<i>P</i> &lt;0.005). Reactions were reported to be more severe in the IL-2 patient group.<sup>2</sup><br><br>The mechanism for the increase in delayed hypersensitivity reactions to iodinated contrast media after IL-2 therapy is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Proleukin</i> (aldesleukin) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; July 2012.</p>\n<p>2. Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Delayed reactions to contrast media after interleukin-2 immunotherapy. <i>Radiology</i>. 1992;183(1):111-114. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1549655\">[PubMed 1549655]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8460":"<p><b>Title</b> Saccharomyces boulardii / Antifungal Agents (Systemic, Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> It is probably best to avoid concomitant use of systemic antifungals (or non-absorbed oral antifungals) during treatment with saccharomyces boulardii.</p>\n<div>\n <p><b>Antifungal Agents (Systemic, Oral) Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex, Anidulafungin, Caspofungin, Fluconazole, Flucytosine, Griseofulvin, Isavuconazonium Sulfate, Itraconazole, Ketoconazole (Systemic), Micafungin, Miconazole (Oral), Nystatin (Oral), Posaconazole, Terbinafine (Systemic), Voriconazole</p>\n</div> \n<p><b>Discussion</b> It is likely that systemic antifungal agents (and, possibly, non-absorbed oral agents) will diminish the activity of saccharomyces boulardii, and interfere with its therapeutic intent. The manufacturer recommends against concomitant use of saccharomyces boulardii and antifungal agents.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Florastor</i> (saccharomyces boulardii) [prescribing information]. San Bruno, CA: Biocodex; January 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8461":"<p><b>Title</b> Antipsychotic Agents / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for the development of significant extrapyramidal symptoms during concomitant therapy with antipsychotics and lithium. The effects may manifest within a few hours of concurrent therapy or take several weeks. Dosing adjustments may be necessary. Monitor for decreased serum concentrations/therapeutic effects of phenothiazines if concurrently administered with lithium.</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Although at times lithium and antipsychotic agents are used concurrently and advantageously, several reports describe the development of significant neurotoxic symptoms that warrant consideration. One chlorpromazine-stable patient (200-600 mg/day for 5 years) developed stiffness of his face, arms, and legs, along with Parkinson-like tremor in his hands, within a day of initiating lithium (900 mg/day).<sup>1</sup> Extrapyramidal symptoms occurred in another patient receiving haloperidol within hours of starting lithium therapy.<sup>1</sup> Similar cases, some including the diagnosis of neuroleptic malignant syndrome (NMS), have been reported in patients receiving lithium along with clozapine,<sup>2,3</sup> fluphenazine,<sup>4,5</sup> haloperidol,<sup>6,7</sup> loxapine,<sup>8,9</sup> olanzapine,<sup>10,11</sup> thioridazine,<sup>12,13</sup> and thiothixene.<sup>14</sup> The mechanism(s) of these presumed interactions is unknown. In addition to these pharmacodynamic effects, lithium administration has been demonstrated to decrease serum chlorpromazine concentrations enough to reduce the therapeutic efficacy of the product.<sup>15,16</sup> The mechanism of this pharmacokinetic interaction is unknown, although inhibition of gastric emptying by lithium leading to decreased chlorpromazine serum concentrations is a proposed mechansim.<sup>17</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Addonizio G. Rapid induction of extrapyramidal side effects with combined use of lithium and neuroleptics. <i>J Clin Psychopharmacol</i>. 1985;5(5):296-298. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4044883\">[PubMed 4044883]</a></p>\n<p>2. Lemus CZ, Lieberman JA, Johns CA. Myoclonus during treatment with clozapine and lithium: the role of serotonin. <i>Hillside J Clin Psychiatry</i>. 1989;11(2):127-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2488054\">[PubMed 2488054]</a></p>\n<p>3. Blake LM, Marks RC, Luchins DJ. Reversible neurologic symptoms with clozapine and lithium. <i>J Clin Psychopharmacol</i>. 1992;12(4):297-299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1527237\">[PubMed 1527237]</a></p>\n<p>4. Sachdev PS. Lithium potentiation of neuroleptic-related extrapyramidal side-effects. <i>Am J Psychiatry</i>. 1986;143(7):942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3087223\">[PubMed 3087223]</a></p>\n<p>5. Singh SV. Lithium carbonate/fluphenazine decanoate producing irreversible brain damage. <i>Lancet</i>. 1982;2(8292):278. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6124706\">[PubMed 6124706]</a></p>\n<p>6. Cohen WJ, Cohen NH. Lithium carbonate, haloperidol, and irreversible brain damage. <i>JAMA</i>. 1974;230(9):1283-1287. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479505\">[PubMed 4479505]</a></p>\n<p>7. Baastrup PC, Hollnagel P, Sorensen R, Schou M. Adverse reactions in treatment with lithium carbonate and haloperidol. <i>JAMA</i>. 1976;236(23):2645-2646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1036539\">[PubMed 1036539]</a></p>\n<p>8. de la Gandara J, Dominguez RA. Lithium and loxapine: a potential interaction. <i>J Clin Psychiatry</i>. 1988;49(3):126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3126179\">[PubMed 3126179]</a></p>\n<p>9. Fuller MA, Sajatovic M. Neurotoxicity resulting from a combination of lithium and loxapine. <i>J Clin Psychiatry</i>. 1989;50(5):187. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2715145\">[PubMed 2715145]</a></p>\n<p>10. Tuglu C, Erdogan E, Abay E. Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report. <i>J Korean Med Sci</i>. 2005;20(4):691-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16100469\">[PubMed 16100469]</a></p>\n<p>11. Berry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. <i>Pharmacotherapy</i>. 2003;23(2):255-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12587815\">[PubMed 12587815]</a></p>\n<p>12. Bailine SH, Doft M. Neurotoxicity induced by combined lithium-thioridazine treatment. <i>Biol Psychiatry</i>. 1986;21(8-9):834-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3089336\">[PubMed 3089336]</a></p>\n<p>13. Spring GK. Neurotoxicity with combined use of lithium and thioridazine. <i>J Clin Psychiatry</i>. 1979;40(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=106047\">[PubMed 106047]</a></p>\n<p>14. Fetzer J, Kader G, Danahy S. Lithium encephalopathy: a clinical, psychiatric, and EEG evaluation. <i>Am J Psychiatry</i>. 1981;138(12):1622-1623. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6118069\">[PubMed 6118069]</a></p>\n<p>15. Rivera-Calimlim L, Nasrallah H, Strauss J, Lasagna L. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. <i>Am J Psychiatry</i>. 1976;133(6):646-652. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5901\">[PubMed 5901]</a></p>\n<p>16. Rivera-Calimlim L, Kerzner B, Karch FE. Effect of lithium on plasma chlorpromazine levels. <i>Clin Pharmacol Ther</i>. 1978;23(4):451-455. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=630793\">[PubMed 630793]</a></p>\n<p>17. Rivera-Calimlim L. Effect of lithium on gastric emptying and absorption of oral chlorpromazine. <i>Psychopharmacol Commun</i>. 1976;2(3):263-272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=996279\">[PubMed 996279]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8462":"<p><b>Title</b> Natalizumab / Vedolizumab</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Vedolizumab may enhance the adverse/toxic effect of Natalizumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of vedolizumab with natalizumab due to the potential for an increased risk of progressive multifocal leukoencephalopathy (PML) and/or other infections.</p> \n<p><b>Discussion</b> According to vedolizumab prescribing information, vedolizumab should not be used together with natalizumab due to the potential for an increased risk of progressive multifocal leukoencephalopathy (PML) and/or other infections.<sup>1</sup> PML typically only occurs in immunocompromised patients, and though it has not been clearly associated with vedolizumab in clinical trials, it has been associated with use of natalizumab, which is another integrin inhibitor that acts somewhat similarly to vedolizumab.<sup>1,2</sup> The disease can progress from days to weeks and can lead to death or severe disability over weeks or months.<br><br>Infections other than PML may also occur with vedolizumab, and concurrent use of vedolizumab with other immunosuppressants, such as natalizumab, may increase that risk.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Entyvio</i> (vedolizumab) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; May 2014.</p>\n<p>2. <i>Tysabri</i> (natalizumab) [prescribing information]. Cambridge, MA: Biogen Idec Inc.; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8463":"<p><b>Title</b> Vedolizumab / Anti-TNF Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of vedolizumab and anti-TNF agents.</p>\n<div>\n <p><b>Anti-TNF Agents Interacting Members</b> Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, InFLIXimab, Lenalidomide, Pomalidomide, Thalidomide</p>\n</div> \n<p><b>Discussion</b> According to vedolizumab prescribing information, patients who are receiving vedolizumab should not receive concurrent anti-TNF agents due to the potential for an increased risk of infection.<sup>1</sup> Vedolizumab use is associated with an increased risk of infection, most commonly upper respiratory, including some serious infections.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Entyvio</i> (vedolizumab) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8464":"<p><b>Title</b> Colchicine / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Colchicine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with tipranavir. Increase monitoring for colchicine-related toxicity when using this combination. Colchicine should not be used in patients with impaired renal and/or hepatic function who are also receiving tipranavir.</p> \n<p><b>Discussion</b> According to tipranavir prescribing information, colchicine concentrations may be increased with concurrent tipranavir.<sup>1</sup> As a result, colchicine and tipranavir should not be used together in patients with renal and/or hepatic dysfunction, and in patients with normal renal and hepatic function, colchicine dose reductions are necessary when used with tipranavir.<br><br>The mechanism for this predicted interaction is tipranavir inhibition of CYP3A-mediated colchicine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8465":"<p><b>Title</b> Pipamperone [INT] / COMT Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> COMT Inhibitors may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of COMT Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving pipamperone in combination with a catechol-O-methyltransferase inhibitor anti-Parkinsons agent for reduced effects of both agents.</p>\n<div>\n <p><b>COMT Inhibitors Interacting Members</b> Entacapone, Tolcapone</p>\n</div> \n<p><b>Discussion</b> Catechol-O-methyltransferase anti-Parkinson agents (which act at least in part by inhibiting degradation of dopamine) and pipamperone (which acts at least in part as a dopamine receptor antagonist) may antagonize each other's actions.<sup>1</sup> Patients receiving these combinations should therefore be monitored closely for reduced effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dipiperon</i> (pipamperone) [summary of product characteristics]. Issy-les-Moulineaux, France: Janssen- Cilag; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8466":"<p><b>Title</b> Cyclophosphamide / Protease Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Protease Inhibitors may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the incidences of neutropenia, infection, and mucositis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients given cyclophosphamide in combination with a protease inhibitor-based antiretroviral regimen may experience higher rates of neutropenia and infection compared with nonneucleoside reverse transcriptase inhibitor-based regimens.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir</p>\n</div> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information states that its use in combination with HIV protease inhibitor-based antiretroviral regimens may increase concentrations of cytotoxic cyclophosphamide metabolites, and consequently increase rates of infection and neutropenia, compared with nonneucleoside reverse transcriptase inhibitor-based antiretroviral regimens in patients treated with cyclophosphamide, doxorubicin, and etoposide (CDE).<sup>1,2</sup> This statement is supported by the results of a review of records of 46 patients treated with CDE for AIDS-related Hodgkin lymphoma, in which infection and neutropenia were more common with protease inhibitor-based regimens but response and survival rates were similar between groups.<sup>3</sup> The exact protease inhibitors used by patients in this review are unclear. Another report describes a greater incidence of severe mucositis when combining CDE with saquinavir-based antiretroviral regimens (with stavudine or stavudine and didanosine), without any difference in myelosuppression or neutropenia.<sup>4</sup> <br><br>In another review, the combination of protease inhibitor-based (indinavir, ritonavir, or saquinavir) antiretroviral regimens with cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) or a similar regimen was associated with greater rates of severe anemia, greater use of colony-stimulating factor support, and a greater incidence of autonomic neurotoxicity compared with no treatment or zidovudine-only treatment;<sup>5</sup> however, leukopenia was similar between groups and opportunistic infections were less common in the protease inhibitor-treated group. At least 3 additional reports describe generally favorable patient outcomes, including improved survival and lower rates of some hematologic and nonhematologic toxicities, in patients treated with modern antiretroviral regimens in combination with lymphoma chemotherapy compared with previous modalities.<sup>6,7,8</sup> However, these analyses give little or no basis for evaluating protease inhibitor-based regimens compared with others.<br><br>The potential mechanism of interaction between cyclophosphamide and protease inhibitor-based antiretroviral regimens is unclear. It is also unclear if any increased risk of neutropenia and infection is due to cyclophosphamide specifically, or if effects truly extend to protease inhibitors in general. Cyclophosphamide may be metabolized to its active form by several enzymes, some of which (eg, CYP3A4) are inhibited substantially by many protease inhibitors while others (eg, CYP2B6) may be variably affected (inhibited, induced, or neither) depending on the protease inhibitor used. In one pharmacokinetic study of patients receiving CHOP for AIDS-associated non-Hodgkin lymphoma, the use of a protease inhibitor-based (indinavir, nelfinavir, or saquinavir) antiretroviral regimen was not associated with a significant change in doxorubicin exposure.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. <i>Blood</i>. 2004;104(9):2943-2946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15238428\">[PubMed 15238428]</a></p>\n<p>4. Sparano JA, Wiernik PH, Hu X, Sarta C, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. <i>Med Oncol</i>. 1998;15(1):50-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9643531\">[PubMed 9643531]</a></p>\n<p>5. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>6. Navarro JT, Ribera JM, Oriol A, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. <i>Br J Haematol</i>. 2001;112(4):909-915. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11298585\">[PubMed 11298585]</a></p>\n<p>7. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). <i>J Clin Oncol</i>. 2004;22(8):1491-1500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15084622\">[PubMed 15084622]</a></p>\n<p>8. Bower M, Powles T, Stebbing J, Thirlwell C. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. <i>J Clin Oncol</i>. 2005;23(6):1328-1329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15718342\">[PubMed 15718342]</a></p>\n<p>9. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8467":"<p><b>Title</b> Isoproterenol / Amitriptyline</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amitriptyline may enhance the arrhythmogenic effect of Isoproterenol. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> A single case report describes a patient who died due to a cardiac arrhythmia as a result of a presumed interaction between inhaled isoproterenol and amitriptyline.<sup>1</sup> The patient was taking an estimated 5 mg of isoproterenol daily for several days prior to her death, as well as theophylline and ephedrine (doses not stated). The authors conclude that it was the addition of amitriptyline to isoproterenol that led to her death. However, it is unclear what role the high dose of isoproterenol, along with additional arrhythmogenic drugs, played in the development of the cardiac arrhythmia. It is difficult to conclude that the combination of amitriptyline and isoproterenol were the sole reason for the patient's death. <br><br>No other reports of this drug interaction have been published and two small studies suggest that amitriptyline may not potentiate the cardiotoxic effects of isoproterenol. One study (N=4) found no change in blood pressure or heart rate with isoprenaline alone compared to the combination of isoprenaline and imipramine.<sup>2</sup> No arrhythmias occurred during the study. Another study (N = 14) examined the heart rate and blood pressure response to isoproterenol before and after 10 months of therapy with either imipramine, desimipramine, or nortriptyline.<sup>3</sup> Prior to tricyclic antidepressant (TCA) therapy, isoproterenol increased systolic blood pressure 16.6 mm Hg while no change in systolic blood pressure was noted with isoproterenol after TCA therapy (p &lt;0.05). Isoproterenol increased heart rate to a similar extent before and after TCA therapy.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kadar D. Letter: Amitriptyline and isoproterenol: fatal drug combination. <i>Can Med Assoc J</i>. 1975;112(5):556-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1116081\">[PubMed 1116081]</a></p>\n<p>2. Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN. Interactions between sympathomimetic amines and antidepressant agents in man. <i>Br Med J</i>. 1973;1(5849):311-315. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4685619\">[PubMed 4685619]</a></p>\n<p>3. Pohl R, Yeragani VK, Balon R. Effects of isoproterenol in panic disorder patients after antidepressant treatment. <i>Biol Psychiatry</i>. 1990;28(3):203-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2165824\">[PubMed 2165824]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8468":"<p><b>Title</b> Cyclophosphamide / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, granulocytopenia may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients given cyclophosphamide in combination with thiazide diuretics may experience higher rates of granulocytopenia than patients not given thiazide diuretics.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in combination with thiazide diuretics may increase the risk of hematotoxicity.<sup>1,2,</sup> In a clinical study of 14 patients with metastatic breast cancer and hypertension, the concomitant use of thiazide diuretics with cyclophosphamide, methotrexate and fluorouracil lowered the mean granulocyte count and granulocyte count nadir by 20% and 26%, respectively.<sup>3</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazide diuretics. <i>Drug Intell Clin Pharm</i>. 1981;15(12):967-970. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7338193\">[PubMed 7338193]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8469":"<p><b>Title</b> Ceritinib / Bradycardia-Causing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of ceritinib with other drugs that can cause bradycardia when possible. If such use cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy. Adjustment of ceritinib therapy (i.e., dose reduction and/or temporary discontinuation) may be necessary for symptomatic bradycardia.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> Bradycardia was reported in 1-3% of patients treated with ceritinib in clinical trials, and the ceritinib prescribing information recommends avoiding concurrent use of other drugs that can cause bradycardia when possible.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zykadia</i> (ceritinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8470":"<p><b>Title</b> Amiodarone / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclophosphamide may enhance the adverse/toxic effect of Amiodarone. Specifically, the risk of pulmonary toxicity may be enhanced. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and amiodarone are given in combination.</p> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in combination with amiodarone may increase the risk of pulmonary toxicity.<sup>1,2</sup> Both agents have been associated with pulmonary toxicity, and 2 published case reports suggest that pulmonary toxicity resulting from their combination may be severe.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Bhagat R, Sporn TA, Long GD, Folz RJ. Amiodarone and cyclophosphamide: potential for enhanced lung toxicity. <i>Bone Marrow Transplant</i>. 2001;27(10):1109-1111. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11438830\">[PubMed 11438830]</a></p>\n<p>4. Gupta S, Mahipal A. Fatal pulmonary toxicity after a single dose of cyclophosphamide. <i>Pharmacotherapy</i>. 2007;27(4):616-618. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17381391\">[PubMed 17381391]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8471":"<p><b>Title</b> Cyclophosphamide / Filgrastim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and filgrastim are given in combination.</p> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in combination with filgrastim or sargramostim may increase the risk of pulmonary toxicity.<sup>1,2</sup> Several published reports describe pulmonary toxicity, sometimes severe or fatal, occurring in patients given colony-stimulating factors during treatment with chemotherapeutic regimens including cyclophosphamide.<sup>3,4,5</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. <i>Respir Med</i>. 1999;93(1):65-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10464852\">[PubMed 10464852]</a></p>\n<p>4. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1998;77(12):2286-2290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9649147\">[PubMed 9649147]</a></p>\n<p>5. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1994;70(5):1009-1013. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7524599\">[PubMed 7524599]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8472":"<p><b>Title</b> Sargramostim / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclophosphamide may enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and sargramostim are given in combination.</p> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in combination with filgrastim or sargramostim may increase the risk of pulmonary toxicity.<sup>1,2</sup> Several published reports describe pulmonary toxicity, sometimes severe or fatal, occurring in patients given colony-stimulating factors during treatment with chemotherapeutic regimens including cyclophosphamide.<sup>3,4,5</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. <i>Respir Med</i>. 1999;93(1):65-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10464852\">[PubMed 10464852]</a></p>\n<p>4. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1998;77(12):2286-2290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9649147\">[PubMed 9649147]</a></p>\n<p>5. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1994;70(5):1009-1013. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7524599\">[PubMed 7524599]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8473":"<p><b>Title</b> Cyclophosphamide / AzaTHIOprine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AzaTHIOprine may enhance the hepatotoxic effect of Cyclophosphamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for hepatotoxicity in patients receiving cyclophosphamide in combination with, or soon after discontinuation of, azathioprine.</p> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in combination with azathioprine may increase the risk of hepatotoxicity (specifically, hepatic necrosis).<sup>1,2</sup> One published case series describes 4 patients who developed hepatotoxicity (3 had evidence of hepatic necrosis) when cyclophosphamide was given during or shortly following discontinuation of azathioprine.<sup>3</sup> The mechanism of this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. <i>Q J Med</i>. 1988;67(252):309-317. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3060893\">[PubMed 3060893]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8474":"<p><b>Title</b> Alpha2-Agonists / Mirtazapine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mirtazapine may diminish the antihypertensive effect of Alpha2-Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the opposing pharmacologic effects of these products, consider avoiding their concurrent use. If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased. Note that tricyclic antidepressants (TCAs) and serotonin/norepinephrine reuptake inhibitors (SNRIs) may also antagonize alpha2-agonist effects, and thus may not be suitable alternatives to mirtazapine.</p>\n<div>\n <p><b>Alpha2-Agonists Interacting Members</b> Apraclonidine, Brimonidine (Ophthalmic), CloNIDine, Dexmedetomidine, GuanFACINE, Lofexidine, Methyldopa, Moxonidine, Rilmenidine, TiZANidine</p>\n</div> \n<p><b>Discussion</b> Blood pressure increased, and shortness of breath was evident, in a patient with previously controlled hypertension taking clonidine, losartan, and metoprolol within a few days of initiating mirtazapine (15 mg/day).<sup>1</sup> The patient required hospital admission and aggressive therapy to regain control of the hypertension. The patient was subsequently controlled on the same antihypertensive regimen noted above when mirtazapine was discontinued. In a second case report, blood pressure rose to 250/130 mmHg approximately 90 minutes after a patient taking clonidine (0.1 mg every 8 hours) received mirtazapine (30 mg/day for 3 days, then 45 mg once).<sup>2</sup> The patient received two doses of intravenous labetalol, and blood pressure returned to 128/76 approximately 10 hours later.<br><br>The most likely mechanistic explanation for these observations is mirtazapine inhibition of alpha2 mediated antihypertensive effects of clonidine. Based on autoradiographic data, binding of clonidine to alpha2-adrenoceptors is reduced in the presence of ®- and (S)-mirtazapine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Abo-Zena RA, Bobek MB, Dweik RA. Hypertensive urgency induced by an interaction of mirtazapine and clonidine. <i>Pharmacotherapy</i>. 2000;20(4):476-478. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10772378\">[PubMed 10772378]</a></p>\n<p>2. Troncoso AL, Gill T. Hypertensive urgency with clonidine and mirtazapine. <i>Psychosomatics</i>. 2004;45(5):449-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15345793\">[PubMed 15345793]</a></p>\n<p>3. Smith DF, Hansen SB, Jakobsen S, et al. Neuroimaging of mirtazapine enantiomers in humans. <i>Psychopharmacology (Berl)</i>. 2008;200(2):273-279. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18566802\">[PubMed 18566802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8475":"<p><b>Title</b> CycloSPORINE (Systemic) / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclophosphamide may enhance the immunosuppressive effect of CycloSPORINE (Systemic). Cyclophosphamide may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients treated with cyclophosphamide may have lower serum cyclosporine concentrations and require higher doses to achieve target serum concentrations.</p> \n<p><b>Discussion</b> Cyclophosphamide US prescribing information warns that its use in patients receiving cyclosporine has been associated with decreased cyclosporine concentrations.<sup>1,2</sup> In a retrospective review of medical records of 103 allogeneic hematopoietic stem cell transplant recipients, use of a conditioning chemotherapy regimen containing cytarabine was associated with 31% lower median serum concentrations of cyclosporine (3 mg/kg intravenously over 10 hours daily from day before transplant to at least day 14 posttransplant, with methotrexate given on days 1, 3, 6, and 11 posttransplant).<sup>3</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>2. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>3. Nagamura F, Takahashi T, Takeuchi M, et al. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. <i>Bone Marrow Transplant</i>. 2003;32(11):1051-1058. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14625575\">[PubMed 14625575]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8476":"<p><b>Title</b> Bradycardia-Causing Agents / Bradycardia-Causing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bradycardia-Causing Agents may enhance the bradycardic effect of other Bradycardia-Causing Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Added caution is warranted with any concurrent use of multiple drugs that are capable of causing or worsening bradycardia. Monitor heart rate and blood pressure more closely, and caution patients about the potential for new-onset or worsened bradycardia and related clinical consequences (e.g., syncope).</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> Concurrent use of multiple drugs that each have a potential to cause bradycardia is expected to increase the risk for clinically relevant bradycardia. Drugs included in this group have a specific labeled warning about their potential to cause/worsen bradycardia, have a specific labeled warning concerning use together with other drugs known to lower heart rate, and/or are considered to have a risk for causing bradycardia based on published studies or case reports and/or known pharmacology.<br><br>Though studies examining the concurrent use of these agents are not available for many of the potential combinations, several reports and studies have described the potential clinical consequences of such use.<sup>1,2,3,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Paulison B, Leos CL. Potential cardiotoxic reaction involving rivastigmine and beta-blockers: a case report and review of the literature. <i>Cardiovasc Toxicol</i>. 2010;10(4):306-310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20865460\">[PubMed 20865460]</a></p>\n<p>2. Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). <i>Drug Saf</i>. 2007;30(11):1063-1071. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17973542\">[PubMed 17973542]</a></p>\n<p>3. Berkenbosch JW, Tobias JD. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. <i>Pediatr Crit Care Med</i>. 2003;4(2):203-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12749653\">[PubMed 12749653]</a></p>\n<p>4. Kinoshita H, Taniguchi T, Nishiguchi M, et al. An autopsy case of combined drug intoxication involving verapamil, metoprolol and digoxin. <i>Forensic Sci Int</i>. 2003;133(1-2):107-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12742696\">[PubMed 12742696]</a></p>\n<p>5. Strauss WE, Parisi AF. Combined use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina. Rationale, efficacy, and adverse effects. <i>Ann Intern Med</i>. 1988;109(7):570-581. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2901816\">[PubMed 2901816]</a></p>\n<p>6. Davis JC, Reiffel JA, Bigger JT Jr. Sinus node dysfunction caused by methyldopa and digoxin. <i>JAMA</i>. 1981;245(12):1241-1243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7206114\">[PubMed 7206114]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8477":"<p><b>Title</b> Levodopa / Dacarbazine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dacarbazine may diminish the therapeutic effect of Levodopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Consider monitoring for diminished response to levodopa in patients treated with dacarbazine.</p> \n<p><b>Discussion</b> A single published case report describes a 49 to 50 year old man who had a reproducibly diminished response to levodopa / benserazide (200 mg / 50 mg single dose when tested by authors under close monitoring) with concomitant administration of intravenous dacarbazine (400 mg) for melanoma.<sup>1,2</sup> Serum dopamine concentrations were similar with and without dacarbazine. The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Merello M, Esteguy M, Perazzo F, Leiguarda R. Impaired levodopa response in Parkinson's disease during melanoma therapy. <i>Clin Neuropharmacol</i>. 1992;15(1):69-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1576600\">[PubMed 1576600]</a></p>\n<p>2. <i>DBL</i> (dacarbazine) [summary of product characteristics]. Melbourne VIC: Hospira Australia Pty Ltd; June 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8478":"<p><b>Title</b> Alfentanil / DiazePAM</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DiazePAM may enhance the CNS depressant effect of Alfentanil. Hypotension may also occur. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The combination of alfentanil and diazepam may result in vasodilation, hypotension, and delayed postoperative recovery. Monitor closely.</p> \n<p><b>Discussion</b> Alfentanil US prescribing information states that its use with or immediately following diazepam may cause vasodilation and hypotension, and delay recovery.<sup>1</sup> In a clinical study of 40 patients 19 to 75 years old, administration of diazepam (0.125 mg/kg) with alfentanil (100-200 mcg/kg) was associated with significantly greater impairment of responsiveness and decreases in blood pressure from baseline compared with administration of alfentanil alone.<sup>2</sup> Six of 40 patients who had respiratory depression in the study had received the diazepam-alfentanil combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Alfenta</i> (alfentanil) [prescribing information]. Lake Forest, IL: Akorn Inc; October 2008.</p>\n<p>2. Silbert BS, Rosow CE, Keegan CR, et al. The effect of diazepam on induction of anesthesia with alfentanil. <i>Anesth Analg</i>. 1986;65(1):71-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3079632\">[PubMed 3079632]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8479":"<p><b>Title</b> Loop Diuretics / Canagliflozin</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations for management of this interaction differ between US and Canadian product labeling</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Canagliflozin may enhance the hypotensive effect of Loop Diuretics. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> According to US product labeling, patients receiving canagliflozin with a loop diuretic should be monitored for symptoms of intravascular volume depletion and hypotension. Canadian product labeling recommends avoiding the combination of canagliflozin and loop diuretics.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> A large pooled analysis of eight controlled phase 3 studies (N=9,439) found that age greater than 75 years, moderate renal impairment (CrCl 30-60 mL/min), and use of loop diuretics were the three factors associated with the largest increase in adverse reactions related to reduced intravascular volume (eg, postural dizziness, orthostatic hypotension, hypotension, dehydration, and syncope).<sup>1,2</sup><br><br>The mechanism of this interaction is excessive intravascular volume depletion due to the osmotic diuretic effect of canagliflozin combined with the volume depleting action of loop diuretics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2013.</p>\n<p>2. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8480":"<p><b>Title</b> Canagliflozin / Efavirenz</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canagliflozin dose adjustment may be appropriate in patients with estimated glomerular filtration rate greater than 60 mL/min/1.73 m2, whereas alternatives should be sought for patients with lower estimated renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Canagliflozin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients with estimated glomerular filtration rate (GFR) greater than 60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require additional glycemic control, consider increasing canagliflozin dose to 300 mg/day during concomitant treatment with efavirenz. Consider alternatives to canagliflozin in patients with estimated GFR between 45 and 60 mL/min/1.73 m2 treated with efavirenz.</p> \n<p><b>Discussion</b> In a clinical study summarized in canagliflozin prescribing information, coadministration of rifampin (600 mg daily for 8 days) decreased the maximum concentration and AUC of canagliflozin (300 mg single dose) by 28% and 51%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of enzymes responsible for the primary glucuronidation of canagliflozin (e.g., UGT1A9, 2B4). Caution and possible therapy modification are encouraged in patients receiving canagliflozin with rifampin as well as other inducers of these enzymes. US and Canadian product labeling mentions phenobarbital, phenytoin, and ritonavir as examples of such inducers<sup>1,2</sup> and Canadian labeling also lists efavirenz, carbamazepine, and St. John's wort as potential inducers.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2013.</p>\n<p>2. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8481":"<p><b>Title</b> Canagliflozin / CarBAMazepine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canagliflozin dose adjustment may be appropriate in patients with estimated glomerular filtration rate greater than 60 mL/min/1.73 m2, whereas alternatives should be sought for patients with lower estimated renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Canagliflozin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients with estimated glomerular filtration rate (GFR) greater than 60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require additional glycemic control, consider increasing canagliflozin dose to 300 mg/day during concomitant treatment with carbamazepine. Consider alternatives to canagliflozin in patients with estimated GFR between 45 and 60 mL/min/1.73 m2 treated with carbamazepine.</p> \n<p><b>Discussion</b> In a clinical study summarized in canagliflozin prescribing information, coadministration of rifampin (600 mg daily for 8 days) decreased the maximum concentration and AUC of canagliflozin (300 mg single dose) by 28% and 51%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of enzymes responsible for the primary glucuronidation of canagliflozin (e.g., UGT1A9, 2B4). Caution and possible therapy modification are encouraged in patients receiving canagliflozin with rifampin as well as other inducers of these enzymes. US and Canadian product labeling mentions phenobarbital, phenytoin, and ritonavir as examples of such inducers<sup>1,2</sup> and Canadian labeling also lists efavirenz, carbamazepine, and St. John's wort as potential inducers.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2013.</p>\n<p>2. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8482":"<p><b>Title</b> Canagliflozin / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: Canagliflozin dose adjustment may be appropriate in patients with estimated glomerular filtration rate greater than 60 mL/min/1.73 m2, whereas alternatives should be sought for patients with lower estimated renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Canagliflozin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients with estimated glomerular filtration rate (GFR) greater than 60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require additional glycemic control, consider increasing canagliflozin dose to 300 mg/day during concomitant treatment with St Johns Wort. Consider alternatives to canagliflozin in patients with estimated GFR between 45 and 60 mL/min/1.73 m2 treated with St Johns Wort.</p> \n<p><b>Discussion</b> In a clinical study summarized in canagliflozin prescribing information, coadministration of rifampin (600 mg daily for 8 days) decreased the maximum concentration and AUC of canagliflozin (300 mg single dose) by 28% and 51%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of enzymes responsible for the primary glucuronidation of canagliflozin (e.g., UGT1A9, 2B4). Caution and possible therapy modification are encouraged in patients receiving canagliflozin with rifampin as well as other inducers of these enzymes. US and Canadian product labeling mentions phenobarbital, phenytoin, and ritonavir as examples of such inducers<sup>1,2</sup> and Canadian labeling also lists efavirenz, carbamazepine, and St. John's wort as potential inducers.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Invokana</i> (canagliflozin) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; March 2013.</p>\n<p>2. <i>Invokana</i> (canagliflozin) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8483":"<p><b>Title</b> Efavirenz / Reverse Transcriptase Inhibitors (Non-Nucleoside)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Efavirenz. Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of Efavirenz. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Combination therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs) has not been shown to be beneficial and significant changes in plasma concentrations may occur with concomitant use. The manufacturer of efavirenz states these combinations should not be used.</p>\n<div>\n <p><b>Reverse Transcriptase Inhibitors (Non-Nucleoside) Interacting Members</b> Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine</p>\n</div> \n<p><b>Discussion</b> Interaction studies conducted by the manufacturer of etravirine have shown that combination of etravirine with either efavirenz or nevirapine resulted in decreased plasma concentrations of etravirine.<sup>1</sup> Conversely, combination with delavirdine is predicted to result in increased etravirine levels, and possibly reduced delavirdine concentrations. Efavirenz product labeling states that the combination of efavirenz and another non-nucleoside reverse transcriptase inhibitor (NNRTI) has variable effects on the concentration of both efavirenz and the other NNRTI.<sup>2</sup> Given the changes in plasma concentrations and since combination NNRTI therapy has not been demonstrated to be clinically beneficial, concurrent use of these agents should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Intelence</i> (etravirine) [prescribing information]. Raritan, NJ: Tibotec Therapeutics; January 2008.</p>\n<p>2. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8484":"<p><b>Title</b> Clarithromycin / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Clarithromycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider using an alternative antibiotic, such as azithromycin, for patients taking efavirenz. If concomitant therapy cannot be avoided, monitor for decreased therapeutic effect of clarithromycin and increased incidence of skin rash.</p> \n<p><b>Discussion</b> In a study described in the efavirenz prescribing information, when efavirenz (400 mg daily for 7 days) was combined with clarithromycin (500 mg twice daily for 7 days), the AUC, minimum serum concentration (Cmin), and maximum serum concentration (Cmax) of clarithromycin decreased by 39%, 53%, and 26%, respectively. The AUC, Cmin, and Cmax of the 14-OH metabolite of clarithromycin increased by 34%, 26%, and 49% respectively. It was also reported that 46% of subjects developed a rash while receiving the combination of clarithromycin and efavirenz. In another study described in the prescribing information, when azithromycin (600 mg single dose) was combined with efavirenz (400 mg daily for 7 days), the Cmax of azithromycin increased 22%, but no change was seen in azithromycin AUC or Cmin.<br><br>Although the clinical consequence of decreased clarithromycin concentrations is unknown, the manufacturer of efavirenz recommends considering the use of an alternative antibiotic such as azithromycin. Other macrolide antibiotics, such as erythromycin, have not been studied in combination with efavirenz.<br><br>The proposed mechanism of this interaction is efavirenz induction of the CYP3A isoenzymes responsible for the metabolism of clarithromycin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8485":"<p><b>Title</b> Artemether / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Artemether. Concentrations of dihydroartemisinin (active metabolite of artemether) may also be decreased by efavirenz <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use this combination with caution, due to the potential for reduced therapeutic effects of artemether/lumefantrine. Monitor patient responses closely.</p> \n<p><b>Discussion</b> In a clinical study summarized in the efavirenz US prescribing information, coadministration of efavirenz (600 mg daily x 26 days) with artemether/lumefantrine (80/480 mg 6 dose series over 3 days) decreased the maximum concentration (Cmax) and AUC of artemether by 21% and 51%, respectively. The Cmax and AUC of dihydroartemisinin (active metabolite of artemether) decreased by 38% and 46%, respectively.<sup>1,2</sup> Lumefantrine AUC was decreased by 21% with no change in lumefantrine Cmax.<br><br>Efavirenz may induce enzymes mediating the metabolism of artemether and lumefantrine (e.g., CYP3A4). Based on the decreases seen in dihydroartemisinin exposure, secondary metabolism of artemether may be induced as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2014.</p>\n<p>2. Huang L, Parikh S, Rosenthal PJ, et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2012;61(3):310-316. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22918158\">[PubMed 22918158]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8486":"<p><b>Title</b> DilTIAZem / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of DilTIAZem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for reduced pharmacologic effect of diltiazem when coadministered with efavirenz. Diltiazem dose adjustments should be guided by clinical response (eg, heart rate, blood pressure). No dose adjustment of efavirenz is necessary when administered with diltiazem.</p> \n<p><b>Discussion</b> In a clinical study described in the US efavirenz prescribing information, when efavirenz (600 mg daily for 14 days) was combined with diltiazem (240 mg for 7 days), the AUC, minimum serum concentration (Cmin), and maximum serum concentration (Cmax) of diltiazem was decreased by 69%, 63%, and 60% respectively. The manufacturer of efavirenz states that although no other calcium channel blockers have been evaluated for their interaction potential with efavirenz, reduced plasma concentrations of the calcium channel blocker, especially those metabolized by CYP3A (eg, felodipine, nifedipine, nicardipine, verapamil), are possible.<br><br>The proposed mechanism of this interaction is efavirenz induction of the CYP3A isoenzymes responsible for the metabolism of diltiazem.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8487":"<p><b>Title</b> Calcium Channel Blockers / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for reduced pharmacologic effect of calcium channel blockers when coadministered with efavirenz. Dose adjustments should be guided by clinical response (eg, heart rate, blood pressure).</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study described in the US efavirenz prescribing information, when efavirenz (600 mg daily for 14 days) was combined with diltiazem (240 mg for 7 days), the AUC, minimum serum concentration (Cmin), and maximum serum concentration (Cmax) of diltiazem decreased by 69%, 63%, and 60%, respectively. The manufacturer of efavirenz states that although no other calcium channel blockers have been evaluated for their interaction potential with efavirenz, reduced plasma concentrations of the calcium channel blocker, especially those metabolized by CYP3A (eg, felodipine, nifedipine, nicardipine, verapamil), are possible.<br><br>The proposed mechanism of this interaction is efavirenz induction of the CYP3A isoenzymes responsible for the metabolism of diltiazem.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sustiva</i> (efavirenz) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8488":"<p><b>Title</b> Apixaban / Naproxen</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Naproxen may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased. Naproxen may increase the serum concentration of Apixaban. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and naproxen. The risks likely vary according to the naproxen dose and anticipated duration of use. Other NSAIDs are also likely to significantly interact with apixaban to at least some degree. Monitor patients extra closely for signs and symptoms of bleeding with any concurrent use, and counsel patients about the increased risk of bleeding and the need to promptly report any signs or symptoms of possible bleeding.</p> \n<p><b>Discussion</b> The apixaban AUC and maximum serum concentration (Cmax) were increased by an average of 55% and 61%, respectively, in a randomized study of 21 healthy subjects who were given apixaban 10 mg and naproxen 500 mg concurrently.<sup>1</sup> The AUC or Cmax of naproxen did not appear to be affected by the concurrent use of apixaban. Naproxen may inhibit p-glycoprotein, thereby increasing apixaban absorption and systemic apixaban exposure.<sup>1</sup><br><br>Independent of the potential for a pharmacokinetic interaction between these agents, the combination of apixaban anticoagulant effects and naproxen antiplatelet effects may increase bleeding risk. Concomitant use of aspirin with apixaban has been shown to increase bleeding risk from 1.8% per year to 3.4% per year in patients with atrial fibrillation.<sup>2,3</sup> Apixaban combined with aspirin and/or clopidogrel was associated with an increased risk of major bleeding (1.3% versus 0.5%) for post-acute coronary syndrome (ACS) high-risk patients in a randomized controlled trial that was terminated early due to bleeding events.<sup>4</sup> In a phase 2 trial, doses above the approved maximum dose (10 mg/day) were associated with an increased risk of bleeding whereas therapeutic doses (i.e., 10 mg/day or less) showed only a non-significant increase in bleeding events.<sup>5</sup> Patients using dual antiplatelet therapy (clopidogrel and aspirin) together with apixaban had more bleeding events in the study. The use of these medications concomitantly is not contraindicated unless there is active bleeding,<sup>2</sup> but clinical benefit and risk should be assessed for each patient.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban [published online ahead of print April 2, 2014]. <i>Br J Clin Pharmacol</i>. doi:10.1111/bcp.12393 . <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24697979\">[PubMed 24697979]</a></p>\n<p>2. Eliquis (apixaban) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; March 2014.</p>\n<p>3. Granger CB, Alexander JH, McMurrary JJ, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOLE). <i>N Engl J Med</i>. 2011;365(11):981-992. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21870978\">[PubMed 21870978]</a></p>\n<p>4. Alexander JH, Lopes RD, James S, et al; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. <i>N Engl J Med</i>. 2011;365(8):699-708. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21780946\">[PubMed 21780946]</a></p>\n<p>5. Alexander JH, Becker RC, Bhatt DL, et al; APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome. <i>Circulation</i>. 2009;119(22):2877-2885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19470889\">[PubMed 19470889]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8489":"<p><b>Title</b> Salmeterol / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Salmeterol. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of tipranavir/ritonavir and salmeterol is not recommended due to the potential for an increased risk of salmeterol-related adverse cardiovascular events.</p> \n<p><b>Discussion</b> According to tipranavir prescribing information, concomitant administration of tipranavir/ritonavir is not recommended because such use may increase both the plasma concentrations and cardiovascular adverse effects of salmeterol.<sup>1</sup> Whether this concern is primarily related to tipranavir, ritonavir (which is used to “boost” tipranavir concentrations), or both is uncertain. The salmeterol prescribing information cautions that concurrent use of strong CYP3A4 inhibitors is not recommended, and that warning specifically includes ritonavir as an example of a strong CYP3A4 inhibitor.<sup>2</sup> The degree to which tipranavir alone inhibits CYP3A4 is uncertain, but appears to be less substantial, as tipranavir alone may even induce CYP3A4.<sup>3</sup> Nevertheless, as tipranavir must always be given with ritonavir, the net effect is expected to be CYP3A4 inhibition.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Serevent</i> (salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2014.</p>\n<p>3. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8490":"<p><b>Title</b> Protease Inhibitors / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Protease Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Combined use of another protease inhibitor with tipranavir/ritonavir is not recommended. As tipranavir must be used with a low boosting dose of ritonavir, this interaction warning does not apply to such low dose ritonavir, but use of higher, therapeutic ritonavir doses with tipranavir is not recommended.</p>\n<div>\n <p><b>Protease Inhibitors Interacting Members</b> Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, Saquinavir, Tipranavir<br><b>Exception</b> Ritonavir</p>\n</div> \n<p><b>Discussion</b> According to the tipranavir prescribing information, significant interactions were observed when tipranavir/ritonavir (TPV/r) was added to regimens containing certain other ritonavir (RTV)-boosted protease inhibitors. Specifically, steady-state minimum serum concentrations (Cmin) of atazanavir (ATZ), saquinavir (SQV), amprenavir (APV), and lopinavir (LPV) were reduced by an average of 81%, 80%, 56%, and 52%, respectively, within several days of the addition of TPV/r (500 mg/100 mg or 500 mg/200 mg twice daily).<sup>1</sup> Reductions in the AUC and maximum serum concentrations (Cmax) of the other protease inhibitors were also observed, with the average ATZ, SQV, LPV, and APV AUC decreased by 68%, 76%, 55%, and 44%, respectively, and the average Cmax decreased by 57%, 70%, 47%, and 39%, respectively.<sup>1</sup> Overall poor virologic response was predicted by the reduced efficacy in median viral load decrease in dual-boosted treatment compared with single TPV/r treatment, though no difference in virologic response was observed between patients who did or did not reach therapeutic concentrations for the second protease inhibitor.<br><br>The mechanism of this interaction is uncertain, but TPV-mediated induction of protease inhibitor metabolism via CYP3A4 is one likely explanation.<sup>1,2</sup> The manner in which TPV alone affects CYP3A4 is uncertain, but it has been characterized as primarily a CYP3A inducer.<sup>2</sup> However, since TPV must always be given with RTV, which is a potent CYP3A inhibitor, the net effect is expected to be CYP3A4 inhibition.<sup>1,2</sup> An additional consideration is that TPV may also reduce serum concentrations of RTV, which is often used to boost concentrations of other protease inhibitors. Decreased RTV serum concentrations may further contribute to the reduced concentration of the other protease inhibitor in the regimen.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8491":"<p><b>Title</b> Mycophenolate / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Mycophenolate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving mycophenolate should not receive bile acid sequestrants since it could impair mycophenolate effectiveness by significantly decreasing concentrations of the active metabolite of mycophenolate.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a study described in the mycophenolate prescribing information, administration of mycophenolate mofetil (1500 mg) to volunteers who had been receiving cholestyramine (4g three times daily x 4 days) was associated with a 34% to 39% decrease in the AUC of both mycophenolic acid (active form of mycophenolate) and its glucuronide metabolite.<sup>1,2</sup> Product labeling for mycophenolate states that administration with cholestyramine or other agents that may interfere with enterohepatic recirculation is not recommended.<sup>1</sup> Although other bile acid sequestrants have not been specifically studied with mycophenolate, their effect on the impairment of the enterohepatic circulation of mycophenolate is likely similar to cholestyramine. Colestipol prescribing information warns of the potential for reduced mycophenolate efficacy if these agents are combined.<sup>3</sup><br><br>It is suspected that cholestyramine (and other bile acid sequestrants) bind mycophenolate metabolites in the gastrointestinal tract, preventing their reabsorption and the enterohepatic recirculation that is thought to significantly contribute to sustained MPA concentrations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. CellCept (mycophenolate mofetil) [prescribing information]. San Francisco, CA: Genentech USA Inc; September 2013.</p>\n<p>2. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. <i>Clin Pharmacokinet</i>. 1998;34(6):429-455. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9646007\">[PubMed 9646007]</a></p>\n<p>3. Colestid (colestipol) [prescribing information]. New York, NY: Pfizer Inc; May 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8493":"<p><b>Title</b> Glucagon / Indomethacin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Indomethacin may diminish the therapeutic effect of Glucagon. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients taking indomethacin, monitor for reduced glucagon effect.</p> \n<p><b>Discussion</b> According to a published correspondence, a small clinical study was conducted in which four healthy volunteers were given 1 mg IV glucagon at baseline and after three days of receiving indomethacin 25 mg four times daily.<sup>1</sup> Mean glucose response to glucagon decreased during indomethacin treatment compared to baseline and one patient experienced a drop in blood glucose to 40 mg/dL along with symptoms of hypoglycemia during indomethacin treatment. Glucagon prescribing information also warns glucagon may lose its ability to raise blood glucose or paradoxically may even produce hypoglycemia when combined with indomethacin.<sup>2,3</sup><br><br>The mechanism for this interaction is unknown, although the reduction of hepatic glucose production by indomethacin has been proposed.<sup>1,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmitt JK. Indomethacin and hypoglycemia. <i>Diabetes Care</i>. 1987;10(6):790. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3428054\">[PubMed 3428054]</a></p>\n<p>2. <i>GlucaGen</i> (glucagon) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; December 2011.</p>\n<p>3. <i>GlucaGen</i> (glucagon) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; March 2014.</p>\n<p>4. Miller JD, Ganguli S, Sperling MA. Prostaglandin synthesis inhibitors impair hepatic glucose production in response to glucagon and epinephrine. <i>Diabetes</i>. 1983;32(5):439-444. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6301913\">[PubMed 6301913]</a></p>\n<p>5. Ganguli S, Sperling MA, Frame C, Christensen R. Inhibition of glucagon-induced hepatic glucose production by indomethacin. <i>Am J Physiol</i>. 1979;236(4):E358-E365. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=434198\">[PubMed 434198]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8494":"<p><b>Title</b> Alpha-/Beta-Agonists (Indirect-Acting) / Urinary Acidifying Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Urinary Acidifying Agents may decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of indirect acting alpha-/beta-agonists if a urinary acidifying agent is initiated/dose increased, or for increased effects if a urinary acidifying agent is discontinued/dose decreased.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Indirect-Acting) Interacting Members</b> Amezinium, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), Pseudoephedrine</p>\n <p><b>Urinary Acidifying Agents Interacting Members</b> Ammonium Chloride, Methenamine, Piperazine, Potassium Phosphate, Sodium Acid Phosphate</p>\n</div> \n<p><b>Discussion</b> The urinary excretion of indirect acting alpha/beta agonists (eg, ephedrine, phenylpropanolamine, and pseudoephedrine) may increase when administered concomitantly with urinary acidifying agents, resulting in lower serum concentrations.<sup>1,2,3</sup> Increases in the urinary excretion of ephedrine and pseudoephedrine in the presence of ammonium chloride have been reported.<sup>1,2</sup> In one study, little change in the urinary excretion of phenylpropanolamine was noted in the presence of ascorbic acid, however the ability of ascorbic acid to acidify the urine is limited, and urinary pH was not lower than in control patients who did not receive ascorbic acid.<sup>3</sup> The clinical outcome of this interaction is unknown. Decreased effect of the indirect acting alpha/beta agonist may be observed. <br><br>The proposed mechanism of this interaction is that in an acidic environment indirect acting alpha-/beta-agonists exist more in an ionized, less reabsorbable, form. Thus, less drug is reabsorbed, and a greater urinary excretion rate is observed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wilkinson GR, Beckett AH. Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urinary volume output. <i>J Pharmacol Exp Ther</i>. 1968;162(1):139-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p>2. Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. <i>Clin Pharmacol Ther</i>. 1971;12(1):62-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5541135\">[PubMed 5541135]</a></p>\n<p>3. Zimmerman CL. The effect of urinary pH modification on the disposition of phenylpropanolamine. <i>Pharm Res</i>. 1988;5(2):120-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2854630\">[PubMed 2854630]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8495":"<p><b>Title</b> Alpha-/Beta-Agonists (Indirect-Acting) / Alkalinizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of indirect acting alpha-/beta-agonists if an alkalinizing agent is initiated/dose increased, or for decreased effects if an alkalinizing agent is discontinued/dose decreased.</p>\n<div>\n <p><b>Alkalinizing Agents Interacting Members</b> Potassium Citrate, Sodium Bicarbonate, Sodium Citrate, Sodium Lactate, Tromethamine</p>\n <p><b>Alpha-/Beta-Agonists (Indirect-Acting) Interacting Members</b> Amezinium, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), Pseudoephedrine</p>\n</div> \n<p><b>Discussion</b> Two studies report at least a doubling in the serum half-life of pseudoephedrine after alkanization of the urine with sodium bicarbonate.<sup>1,2</sup> In another study, when subjects' urine was alkalized with oral sodium bicarbonate, the AUC of phenylpropanolamine increased by almost 50%.<sup>3</sup> Decreases in urinary excretion in the presence of sodium bicarbonate have also been reported with ephedrine and phenylpropanolamine.<sup>4,5</sup> <br><br>The proposed mechanism of this interaction is that in a basic environment indirect acting alpha-/beta-agonists exist more in a non-ionized, reabsorbable, form. Thus, more drug is reabsorbed, leading to reduced urinary excretion and increased drug exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brater DC, Kaojarern S, Benet LZ, et al. Renal excretion of pseudoephedrine. <i>Clin Pharmacol Ther</i>. 1980;28(5):690-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7438686\">[PubMed 7438686]</a></p>\n<p>2. Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. <i>Clin Pharmacol Ther</i>. 1971;12(1):62-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5541135\">[PubMed 5541135]</a></p>\n<p>3. Zimmerman CL, O'Connell MB, Soria I. The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine. <i>Pharm Res</i>. 1990;7(1):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2300545\">[PubMed 2300545]</a></p>\n<p>4. Wilkinson GR, Beckett AH. Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urinary volume output. <i>J Pharmacol Exp Ther</i>. 1968;162(1):139-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p>5. Zimmerman CL. The effect of urinary pH modification on the disposition of phenylpropanolamine. <i>Pharm Res</i>. 1988;5(2):120-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2854630\">[PubMed 2854630]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8496":"<p><b>Title</b> Alpha-/Beta-Agonists (Indirect-Acting) / Carbonic Anhydrase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbonic Anhydrase Inhibitors may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of indirect acting alpha/beta agonists if a carbonic anhydrase inhibitor (CAI) is initiated/dose increased, or for decreased effects if a CAI is discontinued/dose decreased.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists (Indirect-Acting) Interacting Members</b> Amezinium, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), Pseudoephedrine</p>\n <p><b>Carbonic Anhydrase Inhibitors Interacting Members</b> AcetaZOLAMIDE, Brinzolamide, Dichlorphenamide, Dorzolamide, MethazolAMIDE, Sulthiame, Topiramate, Zonisamide</p>\n</div> \n<p><b>Discussion</b> Two studies report at least a doubling in the serum half-life of pseudoephedrine after alkanization of the urine with sodium bicarbonate.<sup>1,2</sup> In another study, when subjects' urine was alkalized with oral sodium bicarbonate, the AUC of phenylpropanolamine increased by almost 50%.<sup>3</sup> Decreases in urinary excretion in the presence of sodium bicarbonate have also been reported with ephedrine and phenylpropanolamine.<sup>4,5</sup> Other agents that alkalinize the urine (eg, carbonic anhydrase inhibitors) would likely have a similar effect. One study did report a reduction in the early detection of pseudoephedrine in the urine after administration of the carbonic anhydrase inhibitor acetazolamide.<sup>6</sup><br><br>The proposed mechanism of this interaction is that in a basic environment, indirect acting alpha-/beta-agonists exist more in a non-ionized, reabsorbable, form. Thus, more drug is reabsorbed, leading to reduced urinary excretion and increased drug exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Brater DC, Kaojarern S, Benet LZ, et al. Renal excretion of pseudoephedrine. <i>Clin Pharmacol Ther</i>. 1980;28(5):690-694. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7438686\">[PubMed 7438686]</a></p>\n<p>2. Kuntzman RG, Tsai I, Brand L, Mark LC. The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma. <i>Clin Pharmacol Ther</i>. 1971;12(1):62-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5541135\">[PubMed 5541135]</a></p>\n<p>3. Zimmerman CL, O'Connell MB, Soria I. The effects of urine pH modification on the pharmacokinetics and pharmacodynamics of phenylpropanolamine. <i>Pharm Res</i>. 1990;7(1):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2300545\">[PubMed 2300545]</a></p>\n<p>4. Wilkinson GR, Beckett AH. Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urinary volume output. <i>J Pharmacol Exp Ther</i>. 1968;162(1):139-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5656593\">[PubMed 5656593]</a></p>\n<p>5. Zimmerman CL. The effect of urinary pH modification on the disposition of phenylpropanolamine. <i>Pharm Res</i>. 1988;5(2):120-122. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2854630\">[PubMed 2854630]</a></p>\n<p>6. Delbeke FT, Debackere M. The influence of diuretics on the excretion and metabolism of doping agents: Part VI. Pseudoephedrine. <i>Biopharm Drug Dispos</i>. 1991;12(1):37-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2039811\">[PubMed 2039811]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8497":"<p><b>Title</b> Succinylcholine / Bambuterol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bambuterol may enhance the therapeutic effect of Succinylcholine. Bambuterol may increase the serum concentration of Succinylcholine. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of enhanced neuromuscular blockade and delayed recovery from succinylcholine. Considering the long duration of bambuterol activity, this potential interaction may persist for at least 10 to 16 hours following bambuterol administration.</p> \n<p><b>Discussion</b> The recovery from succinylcholine was delayed by approximately 1.3- to 4-fold with concurrent bambuterol in several different clinical studies (n=9 to 25 bambuterol-treated subjects).<sup>1,2,3,4</sup> Similarly, bambuterol was shown to inhibit plasma cholinesterase activity by up to 91%.<sup>1,2,3</sup> These effects did exhibit some dose-dependency, with generally greater delays in recovery from succinylcholine with bambuterol 30 mg (approximately 2- to 4-fold)<sup>2,3</sup> than with bambuterol 10 mg to 20 mg (approximately 1.3- to 2.5-fold).<sup>1,4</sup> The effects also appear to be relatively long-lasting, with a similar degree of inhibition when bambuterol is given 2 hours or 10-16 hours prior to succinylcholine. The degree to which variant forms of cholinesterase are inhibited by bambuterol is not clear, though one study did examine this, enrolling 9 subjects who were heterozygous for abnormal cholinesterase and finding an approximate 1.5- to 2.5-fold delay in recovery from succinylcholine, suggesting that variant forms of cholinesterase may interact in a manner similar to wild-type cholinesterase.<sup>1</sup><br><br>The mechanism of this interaction appears to be inhibition of the plasma cholinesterase metabolism of succinylcholine by the carbamate moieties that are released from bambuterol as it is converted to its active metabolite terbutaline in vivo. The active metabolite terbutaline does not appear to have any significant cholinesterase-inhibiting activity.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bang U, Viby-Mogensen J, Wiren JE. The effect of bambuterol on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. <i>Acta Anaesthesiol Scand</i>. 1990;34(7):600-604. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2244450\">[PubMed 2244450]</a></p>\n<p>2. Bang U, Viby-Mogensen J, Wiren JE, Skovgaard LT. The effect of bambuterol (carbamylated terbutaline) on plasma cholinesterase activity and suxamethonium-induced neuromuscular blockade in genotypically normal patients. <i>Acta Anaesthesiol Scand</i>. 1990;34(7):596-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2244449\">[PubMed 2244449]</a></p>\n<p>3. Fisher DM, Caldwell JE, Sharma M, Wiren JE. The influence of bambuterol (carbamylated terbutaline) on the duration of action of succinylcholine-induced paralysis in humans. <i>Anesthesiology</i>. 1988;69(5):757-759. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3056118\">[PubMed 3056118]</a></p>\n<p>4. Staun P, Lennmarken C, Eriksson LI, Wiren JE. The influence of 10 mg and 20 mg of bambuterol on the duration of succinylcholine-induced neuromuscular blockade. <i>Acta Anaesthesiol Scand</i>. 1990;34(6):498-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2239124\">[PubMed 2239124]</a></p>\n<p>5. Slater RM, From RP, Sum Ping JS, Pank JR. Changes in plasma potassium and neuromuscular blockade following suxamethonium in patients pre-treated with terbutaline. <i>Eur J Anaesthesiol</i>. 1991;8(4):281-286. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1651859\">[PubMed 1651859]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8498":"<p><b>Title</b> Disopyramide / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Disopyramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of disopyramide and itraconazole. Itraconazole US prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> Itraconazole US prescribing information lists its combination with disopyramide as contraindicated due to the potential for increased disopyramide exposure and excessive QTc interval prolongation.<sup>1</sup> Itraconazole is expected to increase disopyramide exposure primarily via inhibition of its CYP3A-mediated metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sporanox</i> (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; June 2014.</p>\n<p>2. Zhang L, Fitzloff JF, Engel LC, Cook CS. Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. <i>Xenobiotica</i>. 2001;31(2):73-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11407536\">[PubMed 11407536]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}